{
  "name" : "twin.sci-hub.se_6645_d8b4ebef8fa8ef0867a363c70cdc6a43_hassan2017.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Evolution and clinical translation of drug delivery nanomaterials",
    "authors" : [ "Shabir Hassana", "Gyan Prakasha", "Ayca Bal Ozturka", "Saghi Saghazadeha", "Muhammad Farhan Sohail", "Jungmok Seoa", "Mehmet Remzi Dokmecia", "Yu Shrike Zhanga", "Ali Khademhosseinia" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "Contents lists available at ScienceDirect\nNano Today\njourna l homepage: www.e lsev ier .com/ locate /nanotoday\nReview\nEvolution and clinical translation of drug delivery nanomaterials\nShabir Hassana,b,1, Gyan Prakasha,b,1, Ayca Bal Ozturka,b,f, Saghi Saghazadeha,b, Muhammad Farhan Sohail a,b, Jungmok Seoa,b,c, Mehmet Remzi Dokmecia,b, Yu Shrike Zhanga,b,∗, Ali Khademhosseinia,b,d,e,∗\na Biomaterials Innovation Research Center, Division of Engineering in Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, MA 02139, USA b Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA c Center for Biomaterials, Korea Institute of Science and Technology, Seoul 02792, Republic of Korea d Nanotechnology Center, King Abdulaziz University, Jeddah 21569, Saudi Arabia e Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Seoul 143-701, Republic of Korea f İstinye University, Faculty of Pharmacy, 34010, Zeytinburnu, Istanbul, Turkey\na r t i c l e i n f o"
    }, {
      "heading" : "Article history:",
      "text" : "Received 19 April 2017 Received in revised form 15 June 2017 Accepted 27 June 2017 Available online 2 August 2017"
    }, {
      "heading" : "Keywords:",
      "text" : "Drug delivery Inorganic nanomaterial Polymeric nanomaterial Liposomes Clinical trials FDA approval\na b s t r a c t\nWith the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterialbased drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rate and bio-distribution still exist, thus making their successful translation to clinical application very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review, the stress has been made on the evolution of nanomaterials that are under different stages of clinical trials or have been approved by the United States Food and Drug Administration (FDA).\n© 2017 Elsevier Ltd. All rights reserved."
    }, {
      "heading" : "Contents",
      "text" : "Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .92 Inorganic nanomaterials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92\nGold nanoparticles (AuNPs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92 Iron oxide nanoparticles (IONPs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 Silica nanoparticles (SiNPs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 Quantum dots (QDs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 Polymeric nanomaterials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 Polymer-drug conjugates (polymeric prodrugs) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 Polymeric nanoparticles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 Micelles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .96 Nanogels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .97\n∗ Corresponding authors at: Biomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA.\nE-mail addresses: yszhang@research.bwh.harvard.edu (Y.S. Zhang), alik@bwh.harvard.edu (A. Khademhosseini). 1 Equal contribution.\nhttp://dx.doi.org/10.1016/j.nantod.2017.06.008 1748-0132/© 2017 Elsevier Ltd. All rights reserved.\nDendrimers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97 Lipid-based nanomaterials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98\nLiposomal synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98 Chemo-responsive liposomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .98 Long-circulating liposomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98 Targeted liposomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 FDA approval and clinical trials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Inorganic nanomaterials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Polymer-based nanomaterials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Liposomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Challenges in clinical approvals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103"
    }, {
      "heading" : "Introduction",
      "text" : "The fascinating world of nanomaterials and their various applications is not new. As early as 2500 BC, natural asbestos was used to increase the reinforcement of a ceramic mixture for decorative purposes [1]. The famous Lycurgus cup made by the Romans in the 4th century AD displayed different colors during the day and when illuminated from inside at night [2]. This gave the first definite evidence into the synthesis and application of gold colloids. Mesopotamians in the 9th century AD introduced silver and/or copper glazed ceramics [3]. It was not until the famous statement, “there is plenty of room at the bottom” from Feynman in 1959 [4] that brought nanotechnology back into focus of the modern scientific world and exactly a decade after, the term “nanotechnology” was coined [5]. Over the years, application of nanomaterials in biomedicine has vastly increased and the introduction of inorganic and polymeric materials further enhanced their role for drug delivery and sustained drug release. Fig. 1 outlines important dates in the evolution of nanomaterials from 2500 BC until today from their discovery/invention to different applications. Not all the listed nanomaterials in Fig. 1 have been approved for clinical use.\nAlthough nanomaterials have found their applications in different fields of research for long, their role in medicine is new and emerging. Due to their small sizes, nanomaterials take a sweet spot that correlates with the sub-micron entities of the biological world, making them especially appropriate for interactions at that scale. Nanomaterials display many distinctive physicochemical properties that differ extensively from their corresponding bulk materials. It is mainly their size-related properties that dictate their physicochemical uniqueness and make them exceptional for various biological applications, e.g. drug delivery, tissue engineering, targeted drug delivery, bio-microelectromechanical systems (bioMEMS), biosensors, microfluidics, and diagnostics [6]. Due to the extraordinary opportunity it offers, nanomaterial-based drug delivery has emerged as the mainstream application of nanotechnology in medicine [7]. In addition to enhancing targeted delivery and controlled release of drugs, nanomaterials assist in improving their circulation time and biodistribution, solubility, intracellular delivery, and crossing biological membranes [8]. Nanomaterials in medicine have been traditionally used for drug delivery applications only; however, new nanoscale platforms have been developed that offer a diagnostic application in addition to their therapeutic ability [9]. Multifunctional nanomaterials have been developed that combine therapeutic, targeting, and imaging capabilities for advanced drug delivery systems and are gaining increasing attention from the research community [10].\nIn this review, we attempt to outline the evolution of nanomaterials for drug delivery applications over the last few decades. We maintain the focus on those materials that have the potential\nfor clinical translation or have been approved for therapeutic purposes by the United States Food and Drug Administration (FDA). Carbon-based nanomaterials for biomedical and tissue engineering applications have been discussed elsewhere [11]. In the first section, nanomaterials of inorganic origin including gold, magnetic, and silica-based materials for drug delivery are discussed. The second section details the applications of polymer-based nanomaterials, where the development and role of dendrimers, polymeric micelles, nanogels, and polymeric nanoparticles are discussed. Lipid-based nanomaterials are explored in the next section, and the last section entails a summary of some of the nanomaterials that have been approved by the FDA for human use."
    }, {
      "heading" : "Inorganic nanomaterials",
      "text" : "Over the last few decades, scientists have actively explored the synthesis of inorganic nanoparticles (INPs) for applications in various fields. In this section, we primarily focus on the synthesis of INPs for diagnostic and therapeutic applications, which require precision engineering of the nanoparticle properties. Fig. 2 outlines important applications of some INPs in diagnostics and drug delivery. The extensive research in the field has provided ample understanding to control the attributes at the nano-bio interface, which has led to numerous successful clinical trials and translations. INPs have also been exploited for their optical properties, which arise due to the quantum size effect, and have been shown to be modulated by control over size for application as effective imaging and contrast agents [12]. Similarly, various chemical modulations have been carried out on their surface, such as polyethylene glycol conjugation (PEGylation) [13], charge modulation, ligand conjugation, and inclusion of stimuli-responsive moieties and small-molecule probes for improved drug efficacy [14]. We further discuss the advances in the synthesis and surface modification of these INPs that have facilitated their successful drug delivery applications."
    }, {
      "heading" : "Gold nanoparticles (AuNPs)",
      "text" : "First scientific insight into the property of AuNPs came from Michael Faraday in 1850 [15], where through synthesis he showed the ability to obtain a ruby red colloidal solution of AuNPs from yellow HAuCl4 gold salt. However, medicinal application of gold salt was not proposed until 1890, as bacteriostatic against tuberculosis [16]. Subsequently, gold was also found to be effective in the treatment of Rheumatoid arthritis in 1927 [16]. This led to prominence of nanogold as therapeutic agent towards various Rheumatoid diseases.\nAuNPs have been widely explored for applications in medicine due to (i) biocompatible nature, (ii) precise control over their\nsize distribution, (iii) modification in shape that includes spheres, nanorods, and cubes, among others, and (iv) ease of modulating surface chemistry through conjugation with various polymers, antibodies, small-molecule therapeutics, and molecular probes [17–19].\nThere are diverse methods for the synthesis of AuNPs, mostly using HAuCl4 as the precursor salt. Most of the methods for the preparation of AuNPs involve reduction of Au3+ ions to Au0, using various reducing agents at different concentrations to control the size of AuNPs. Turkevich et al. introduced citrate salts as the reducing agent for synthesis of AuNPs in 1951 [20]. Researchers\nhave constantly been modifying the Turkevich method to further increase the precision in controlling the size. Furthermore, thiols have also been widely explored as the reducing agent for the synthesis of AuNPs. Shiffrin-Brust used thiols in biphasic solvent along with sodium borohydride and phase transfer reagents to yield 2–4 nm thiol-coated AuNPs [21]. Processes to functionalize AuNPs with different water-soluble surface groups by ligand exchange have been exploited by using thiolated ligands.\nIn 2000, Murray et al. developed post-synthesis ligand substitution on AuNP surface [22]. This method has been extensively modified over the years to have a definitive control on the\nbiophysicochemical interactions of these nanoparticles for low nonspecific protein adsorption [23], active targeting of the tumor [24], and enhanced cellular uptake [25]. In the last two decades, researchers have exploited ligand exchange to conjugate nucleic acids and entrapment of toxic drugs with controlled release. With latest developments in therapeutics, AuNPs have been widely pursued as effective delivery agents for small interfering RNA (siRNA)and DNA-based enzymes (DNAzymes). Kataoka et al. modified the surface of PEGylated AuNPs with hydroxychloroquine for efficient endosomal escape and increased siRNA distribution [26]. Researchers have shown delivery of RNA to regulatory T cells, glioblastoma, and mesenchymal stem cells along with various other therapeutic targets [27–29]. Broadening their use in drug delivery applications, Tang et al. have reported the use of AuNPs-stabilized capsules (AuNPSCs) as an efficient protein delivery system [30]. AuNPSCs consisted of an oil core and were stabilized by amino acids (HKRK) -conjugated cationic AuNPs. These AuNPSCs fused directly with the cell membrane and efficiently delivered proteins such as green fluorescent protein (GFP) and caspase-3 into the cytosol. Further, Ray et al. have demonstrated the versatility of the AuNPSCmediated delivery system by intracellular targeting of the proteins to the nucleus [31]. In a recent work, Mout et al. used programmed assembly of AuNPs with modified Cas9 protein for direct cytosolic delivery and efficient gene editing [32].\nAuNPs also exhibit interesting absorption and scattering properties, which can be modulated by control over their size and shape. Surface Plasmon Resonance (SPR) property has been exploited for numerous in vivo theranostic applications. Gold nanorods (AuNRs) have been quite extensively used for these applications as their length and width can be modulated to obtain SPR bands in the near-infrared (NIR) regions to allow better contrast in biological tissues [33]. Oldenburg et al. synthesized gold nanoshells (AuNSs) through silica nanoparticle-templated growth of gold, which have an absorption band in the NIR region and their optical properties can be tuned by controlling thickness of the gold coating [34]. The photothermal property of the gold nanostructures also allows thermal ablation of solid tumors if the AuNSs are excited by NIR and they have shown promising results in clinical studies towards FDA approval under the name of AuroLase [35].\nUnderstanding of size, shape, and surface properties of AuNPs has culminated into various clinical trials as drug carriers and imaging agents; but a supplementary understanding of their cytotoxicity, bio-distribution, and clearance from the body is required for improving their clinical translation [36]."
    }, {
      "heading" : "Iron oxide nanoparticles (IONPs)",
      "text" : "IONPs have been used since the 1960s as targeted imaging and therapeutic agents. Meyers et al. used an external horseshoe magnet to show accumulation of IONPs as contrast agent in the vascular and lymphatic system of dogs [37]. Application of IONPs in drug delivery was explored by Widder et al. in 1979, by encapsulating IONPs in albumin microspheres along with a chemotherapeutic agent to establish an in vivo delivery method [38]. Since then encapsulated IONPs have been explored for site-specific delivery and entered Phase I clinical trial in 1996 for delivery of epirubicin for treatment of advanced cancer [39]. However, the trial was unsuccessful as most of the IONPs accumulated in the liver.\nIONPs have emerged as a successful class of nanoparticles in clinical translation as numerous IONPs are approved by the FDA for therapeutics and imaging. Magnetite (Fe3O4) nanoparticles have attained such eminence due to (i) extremely low cytotoxicity, (ii) magnetic responsiveness and its tunability, (iii) controlled size and surface modification, and (iv) contrast agent for magnetic resonance imaging (MRI) [40].\nIONPs have different magnetic property than bulk magnetite. These nanoparticles exhibit single-domain magnetic property in the sub-100 nm range, which has maximum coercivity as compared to the bulk magnetite that is multi-domain [41]. Further reduction in the size of IONPs decreases their magnetic anisotropy energy. When thermal energy equals the anisotropy energy, it results in random flipping of the magnetic moment and the nanoparticles exhibit super paramagnetic nature [42]. These superparamagnetic IONPs (SPIONs) heat up when placed in an alternating electric field (hyperthermia) [43]. Subsequently, these particles have been used in vivo for targeting and thermal ablation of tumors. Recently, Espinosa et al. synthesized 20-nm iron oxide nanocube, which were heated with alternating magnetic fields and NIR radiation to show complete ablation of solid tumor in vivo due to increased heating power that they termed as dual-mode activation [44]. These SPIONs have also been extensively used in stem cell engineering for their controlled differentiation, efficient homing, and long-term tracking in cell-based therapies. Researchers used PEGylated SPIONs that were internalized by the mesenchymal stem cells (MSCs) to guide them to the site of injury using external magnetic field. This technique was further exploited by Xu et al. to track the MSCs post-engraftment [45].\nSurface moieties on the IONPs play an eminent role in their bio-distribution, cytotoxicity, cellular uptake, and clearance. The rapid degradation of IONPs results in release of Fe2+/3+ ions that alters levels of ferritin, and inflammatory cytokines and several other reactive oxygen species (ROS)-dependent proteins in cells, increasing their cytotoxicity [46]. Thus, efficient surface coating of these IONPs plays a very important role in their physicochemical property in vivo. For most applications, IONPs are coated with hydrophilic polymers for controlled degradation, as well as decrease in immunogenicity and opsonization. Sakhulkhu et al. analyzed the protein corona on the SPIONs coated with polyvinyl alcohol (PVA) and dextran along with the effect of charge modulation. They showed that dextran had less adsorption of protein as compared to PVA. Further, they found that electrostatic charge played an important role and the negatively charged PVA SPIONs had less protein adsorption (22%) compared to 36% and 41% on positive and neutral PVA-coated SPIONs [47].\nIn 2009, FDA approved ‘Ferumtoxyl’, SPIONs for the treatment of anemia patients with chronic kidney disease. These particles are coated with polyglucose sorbitol carboxymethylether that controls their degradation and improves their pharmacokinetics. In further studies, Zanganeh et al. showed that Ferumtoxyl could polarize macrophages in tumor tissue to pro-inflammatory M1 phenotype, which could constrain the proliferation of subcutaneous adenocarcinomas [48]. They also showed the tendency of the SPIONs to inhibit liver metastasis up to 6 times if Ferumtoxyl was pre-injected in vivo [48]. Currently, these materials are being actively explored for imaging the progression of type 1 diabetes and response of the host to the therapies. SPIONs-based imaging has also been effective in distinguishing non-diabetic patients from the ones with recent onset of diabetes due to enhanced accumulation of SPIONs in pancreases [49]; this discovery led the way for drug delivery to pancreas for diabetes.\nDue to the small sizes of IONPs, macrophages and monocytes generally uptake them by phagocytosis or macro-pinocytosis depending on their surface functionality. These IONPs-loaded macrophages have been actively pursued for in vivo imaging and as drug delivery agents for diseases and injuries that involve increased macrophage accumulation. Macrophage-assisted IONP imaging has been explored for various cancers by taking advantage of tumor-associated macrophages. They have also been explored for imaging in myocardial infarction, myocarditis, aortic aneurysm, and atherosclerosis."
    }, {
      "heading" : "Silica nanoparticles (SiNPs)",
      "text" : "SiNPs provide a new modality to the inorganic nanoparticles due to their rapid degradation in vivo, regulated pore sizes (2–10 nm) for drug encapsulation [50], incorporation of metals for theranostic applications [51], and ease of camouflage by chemical conjugations [52].\nSince their invention in the 1960s, as catalysts due to their large surface-to-volume ratios, they have been actively modified to enhance their absorption properties. In 1968, Stöber et al. proposed synthesis of solid SiNPs by a process based on hydrolysis in ammonium oxide of silyl ethers [53]. This method has been adapted by many laboratories to synthesize SiNPs with sizes from 50 to 3000 nm. Further, researchers recognized the niche realm of SiNPs in drug delivery since the synthesis of mesoporous silica nanoparticles (MSNPs) in 1990’s [54]. They have filled the gap that wouldn’t otherwise be covered by metallic or other inorganic nanomaterials with regards to their degradability, biocompatibility, and drug release rates.\nMSNPs provide an interesting and alternative route to drug delivery as they have nanopores that can encapsulate hydrophobic drugs for efficient delivery, unlike other inorganic nanoparticles. The pore size of MSNPs can be modulated by using various templates, surfactant concentrations, pH, and solvents during the synthesis; this control allows sustained degradation of the particles to deliver various payloads [50]. MSNPs have also been explored as stimuli-responsive drug release systems, where various chemical entities on the surface of MSNPs can be used to control the release of encapsulated drug by a trigger reaction [55]. Essentially, release rates of vancomycin and adenosine triphosphate (ATP) from mesoporous silica nanosphere-based drug delivery systems was controlled by using disulfide bond-reducing molecules, such as dithiothretol (DTT) and mercaptoethanol (ME), as release triggers. This concept is termed as gatekeeping drug delivery system. In the past years, various systems such as AuNPs, IONPs, CdS nanoparticles, and polymers have been used as gatekeepers for controlled release [52,56].\nMSNPs have hydrophilic surfaces, which is attributed to the presence of hydroxyl groups that can be further modified using (3-aminopropyl) triethoxysilane (APTES) to replace with more versatile amine groups. Since early 2000s, many research groups have functionalized MSNPs with antibodies, nucleic acids, and cell membranes to control the biodistribution and reduce the systemic toxicity of MSNPs. In 2012, Parodi et al. used advanced techniques to show enhanced delivery of doxorubicin using cell membranecloaked MSNPs [52]. They demonstrated that MSNPs coated with leucocyte membranes (termed as ‘cloaking’) have reduced cytotoxicity and they efficiently extravasated into the blood vasculature and accumulated near the tumor site in vivo. Recently, physicochemical properties of PEGylated SiNPs have been further exploited by Kim et al. [57]. They used Cornell dots, which completed Phase I trial and is currently under FDA-investigational new drug (IND) for actively targeting melanoma by conjugating vˇ3-integrintargeting peptides to induce ferroptosis in cancer-bearing mice. As researchers proceed to understand the fate of SiNPs and actively pursue their interactions at the nano-bio interface, we can foresee several clinical translations in the near future."
    }, {
      "heading" : "Quantum dots (QDs)",
      "text" : "In the 1980s, researchers discovered that confined SiNPs emitted red light upon illumination with laser [58]. This led to further research in the field of inorganic nanomaterials to produce a range of light-emitting fluorescent INPs known as Quantum Dots (QDs) are very small semiconductor particles, only several nanometres in size, with different optical and electronic properties as compared to\nlarger particles. They are crystalline in nature and comprise of two different periodic group elements with the size varying in the range of 2–10 nm [59]. Understanding of their material composition and size modulation has led to the development of a broad spectrum of fluorescent QDs, with high quantum yield and low photobleaching. Thus, QDs have found various applications in photodynamic therapy, in vivo imaging, and tracking drug biodistribution [59–61].\nOver the years, QDs have been widely explored in theranostics alone and as an adjunct with wide variety of nanomaterials [62]. Cai et al. used pH-responsive ZnO-QDs coordinated with doxorubicin for targeted drug delivery using hyaluronic acid conjugation [63]. They have shown efficient anti-cancer effect of the ZnO-QDs due to dual effect of Zn2+ and doxorubicin.\nQDs have been explored for various applications in vitro and in vivo but they are yet to be approved in clinical trials due to their potential cytotoxicity [64]. This is due to two main issues with QDs: (i) Use of heavy metals in their composition, and (ii) their clearance from the body. Oh et al. analyzed the published literature to elucidate the dominant role of surface properties and size of the QDs on the cytotoxicity [65]. They also assessed the dataset to understand the role of different core-shell QDs and their surface coating and their half maximal inhibitory concentration (IC50) value. This sequential data-mining gives researchers a broad database to comprehend the plethora of work done on QDs for designing more particles that can be used for clinical translation in drug delivery applications and as theranostic agents. To minimize the cytotoxic effect, researchers are exploring Cd-free QDs [66], which have come up as less cytotoxic nanoparticles along with advances in more efficient polymeric coating of the QDs [67,68]."
    }, {
      "heading" : "Polymeric nanomaterials",
      "text" : "Among various nanotherapeutics, polymeric nanoparticles stand out as a versatile class of nanocarriers that allow controlled drug delivery to diseased tissues [69]. The first generation of polymeric nanoparticles are to encapsulate the drug molecules and have a sustained release in time. To manage efficient drug delivery to the target site, various strategies have been developed in the second-generation polymeric nanoparticles by incorporating stimuli-responsive properties (e.g., pH, temperature, or light activation). Third-generation polymeric nanocarriers are represented by multi-functionalities, such as targeting and multi-drug release properties [70]. In this section, we discuss four main types of polymeric nanomaterials: polymer-drug conjugates, micelles, nanogels, and dendrimers."
    }, {
      "heading" : "Polymer-drug conjugates (polymeric prodrugs)",
      "text" : "Polymer-drug conjugates, containing a water-soluble biocompatible polymer backbone and hydrophobic therapeutic agents (Fig. 3a), are one of the most explored polymeric drug delivery platforms [71,72]. Herein, therapeutic agents are covalently bonded to the polymer backbone via a stimuli-responsive spacer (e.g., disulfide, hydrazone, peptide, azo, etc.), which prevents undesirable drug release in blood circulation [73]. Compared to the other conventional polymer-based platforms, these systems generally have enhanced stability, low toxicity, higher drug-loading capacity, and prolonged drug release behaviors [74].\nFast cellular internalization and ineffective drug delivery to cancer tissues are two of the main challenges of polymer conjugates. Wang et al. developed a new endosomal acid-stimulating polymer-drug conjugate platform, poly(2-(methacryloyloxy)ethyl choline phosphate)-b-poly(2-methoxy-2-oxoethyl methacrylatehydrazide doxorubicin) (PCP-DOX) [75]. The drug was released from the polymer backbone inside cancer cells by the cleavage\nof pH-sensitive hydrazone spacer-drug linkage and successfully translocated to the nucleus. Similarly, Wu et al. created a pH/reduction dual-responsive charge-conversional polymeric prodrug decorated with reduction-responsive disulfide units and acid-labile anticancer drugs for efficient co-delivery of doxorubicin and demethylcantharidin for effective cancer therapy [76]. Under acidic pH and in the presence of glutathione (GSH), polymeric nanoparticles exhibited significantly improved cellular uptake and low cytotoxicity. These findings indicated that the prodrug nanoparticle systems provide a promising approach for combination therapy in cancer treatment."
    }, {
      "heading" : "Polymeric nanoparticles",
      "text" : "The concept of polymeric nanoparticles for the delivery of therapeutic agents was first proposed by Speiser and his team in 1969 [77]. They studied polyacrylic nanoparticles for oral drug administration, which was the first attempt to develop nanoparticles for vaccination purposes using tetanus toxoid and human immunoglobulin [77,78]. Since then, polymeric nanoparticles have been engineered from biocompatible and biodegradable natural or synthetic polymers for various drug delivery systems and the efforts of Robert Langer and his team have been at the forefront of popularizing such platforms [79,80]. Depending on the preparation method of the nanoparticles, either nanocapsules or nanospheres can be obtained. Nanocapsules have a vesicular structure consisting of an inner core surrounded by a polymer membrane or coating, while nanospheres have matrix-type structure in which therapeutic agents are homogeneously dispersed (Fig. 3b). When compared with other nanoparticulate platforms, such as micelles and liposomes, polymeric nanoparticles tend to be more stable, especially in biologic fluids after their administration [81].\nThe most outstanding candidates for designing of polymeric nanoparticle-based drug delivery platforms are poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly( -caprolactone) (PCL), and poly(methyl-methacrylate) (PMMA), as synthetic polymers, as well as chitosan, alginate, gelatin, collagen, dextran, heparin, and albumin, as natural polymers. Among the synthetic polymers utilized to date, PLGA-based nanoparticles have received the most considerable attention due\nto their unique characteristics of biocompatibility and drug release tunability. The greatest advantage of this polymer is that its properties, such as molecular weight, drug release rate, hydrophobicity, and biodegradability can be regulated by manipulating lactideto-glycolide (L:G) ratio [82]. For instance, Gumusderelioglu et al. studied the effect of the L:G ratio variations from 70:30 to 90:10 on mitomycin-C release [83]. The increased drug release amounts and rates were observed corresponding to an increase in the glycolide content. Moreover, after three months, PLGA 90:10 and 70:30 nanoparticles released 30 and 70 wt.% of drug, respectively. Among the natural polymers, chitosan-based nanoparticles have emerged as one of the most popular biopolymers used in nanomedicine by virtue of their outstanding merits such as excellent biocompatibility and biodegradability, low toxicity, mucoadhesivity, hemostatic and antimicrobial activity, simple preparation method, and easy functionalization [84–86]. The key advantage of chitosan-based nanoparticles is their strong affinity for negatively charged cell surfaces and in vivo site-specific drug delivery. The release of therapeutic agents from chitosan-based nanoparticles is dependent upon polymer erosion, polymer-drug interactions, and their swelling potential, which are affected by the pH of the medium [87,88]. In a recent study, Wu et al. designed recombinant human interleukin-2 (rhIL-2) and doxorubicin-loaded chitosan-based nanoparticles for the enhanced anticancer activity [89]. Folic acid (FA) was conjugated onto the amino groups of chitosan to obtain active targeting ability. In this system, in vitro acid-responsive release of doxorubicin and prolonged release of rhIL-2 were managed and improved in vivo anticancer activity and reduced side-effect were achieved."
    }, {
      "heading" : "Micelles",
      "text" : "Polymeric micelles, first introduced as therapeutic systems by Bader et al. in 1984 [90], have a spherical core-shell structure, which was formed via self-assembling of amphiphilic block copolymers in aqueous solutions. The hydrophobic core creates a cargo space for entrapment of hydrophobic therapeutic agents, whereas the hydrophilic shell protects the formed micelle against aggregation and prolongs circulation time in blood [91]. Although polymeric micellar drug delivery systems seem to be promising, most of\nthese systems show burst drug release and lack targeting ability. To address this challenge, stimuli-responsive polymeric micellar structures were developed in the late 1980s (Fig. 3c–d).\nCancer cells have the ability to grow in an acidic tumor microenvironment and researchers have been trying to create polymeric micelle nanocarriers that change their surface charge in the intracellular acidic conditions. Dai et al. developed a simple method to design a dual-pH-responsive nanocarrier platform from self-assembly of a block copolymer, poly(2-(diisopropylamino)-ethyl methacrylate-b-poly(4-formyl phenyl methacrylate-co-polyethylene glycol monomethyl ether methacrylate) (PDPA-b-P(FPMA-co-OEGMA)), that responds to two different pH values [92]. This dual pH-responsive behavior not only led to a pH-triggered improved cellular uptake, but also permitted highly efficient drug release in target tissues. Another innovative approach to develop an alternative micellar nanocarrier platform was recently proposed by Xu et al. [93]. They designed novel GSH-responsive polymeric micelles based on PEG-polycarbonate-PEG triblock copolymer. Disulfide bonds on the polymer chain promoted GSH-triggered drug release inside the tumor cells, where GSH is enriched.\nIt is known that the ROS levels in the tumor cells are much higher than healthy cells [94]. In the presence of the ROS, copolymers can be converted into more hydrophilic components [95]. By utilizing this approach, the dissociated polymers can easily pass into the endosomal membrane of tumor cells and release drugs. Recently, in the work by Yu et al., ROS-responsive micelles based on poly(ethylene glycol)-b-poly(diethyl sulfide) (mPEG-PS) copolymers were developed for specific tumor cytosolic drug delivery [94]. The disassembling of micelles was induced by the hydrophobic to hydrophilic conversion of the mPEG-PS core in response to ROSinduced oxidation in vitro. Similarly, dual redox-sensitive micelles for ROS and GSH were developed for cancer treatment. The encapsulated drugs inside the micelles were not only released in response to the increased levels of ROS and GSH in tumor cells, but also could deeply penetrate into tumor layers [96].\nThe stability of the conventional micelles in the systemic circulation is crucial for their use in drug delivery. To enhance their stability, chemical crosslinking of polymeric micelles has been developed by Ding and Liu in 1998 [97]. In a recent work by the Shi et al. in 2015, triblock thermosensitive polymer-based micelles were synthesized and interfacially crosslinked with pH-responsive hydrazone groups [98]. The interfacially crosslinked micelles provided high drug loading capacity and enhanced drug retention under physiological conditions. A recent study by Chung et al. introduced self-assembling micellar complexes conjugated with organic tea extracts for cancer therapy [99].\nWhile the current investigations on stimuli-responsive polymeric micelles are encouraging, their function and fate in vivo are still not understood properly, particularly, how these responsive micellar architectures behave in the human body. In addition, the structural instability and challenges in controlling drug release in biological environments need to be comprehensively addressed."
    }, {
      "heading" : "Nanogels",
      "text" : "Nanogels are hydrophilic or amphiphilic polymeric particles that absorb water and swell [100]. They were developed in the 1990s. They are physically or chemically crosslinked polymeric hydrogel networks with sizes of around 100–200 nm that show swelling behavior with high water-retaining capacity [101]. Compared to other nanocarriers, nanogels possess several significant advantages, such as higher drug loading capacity, enhanced stability, control over particle size, larger surface area, and increased stimuli-responsiveness to pH, temperature, redox conductions, and enzymes [102,103].\nCombination chemotherapy with multiple anticancer drugs has opened up a new strategy to promote synergistic effects, defeat multidrug resistance, and minimize side effects. In this context, pioneering researchers have been trying to develop multi-stimuli-responsive nanogels for the co-encapsulation of hydrophilic and hydrophobic drugs (Fig. 3e). Jin et al. synthesized new multi-stimuli-responsive nanogels, allowing for selective release of hydrophobic and hydrophilic drug molecules [104]. The hydrophilic drug was covalently bonded to the nanogel through a redox-sensitive disulfide spacer. The hydrophobic drug was encapsulated into nanogels through hydrophobic interactions. The release of hydrophobic drug was triggered by temperature, pH, and UV light whereas the hydrophilic drug was released in the presence of a redox reagent. Nanogel-based multi-stimuli-responsive dual-drug delivery platforms offer a great potential especially for combination chemotherapy [105].\nTumor site-sensitive charge- conversional nanoparticles are smart platforms for effective drug delivery and enhanced tumor uptake. Nanogels can be easily converted from a negativelycharged state to a positively charged state in the tumor extracellular acidic conditions, which promotes the efficiency of drug release in the targeted area [106]. Du et al. developed drug-loaded acidsensitive charge conversional nanogels to promote drug release and cellular internalization triggered by the extracellular pH [107]. Poly(2-aminoethyl methacrylate hydrochloride) (PAMA) nanogels were prepared and then decorated with 2,3-dimethylmaleic anhydride (DMMA) to create negatively charged nanoparticles. They showed that both the release of the drugs and cellular internalization of the designed nanogels were improved in the tumor extracellular environment.\nAlthough many studies have shown the efficacy and safety of nanogels as potential targeting vehicles, only few nanogel-based drug delivery systems have reached clinical trials. We believe that innovations in the design of nanogels together with the investigation of various parameters, which determine nanogels’ behavior in vivo, e.g. toxicity, clearance, and cost will help to carry them from bench to bedside."
    }, {
      "heading" : "Dendrimers",
      "text" : "Dendrimers are spherical structures of highly branched synthetic polymeric macromolecules with well-defined monodisperse nanostructures having sizes in the range of 1–100 nm [108–110]. The precise control over the size and chemistry of dendrimers makes them a platform of choice for an ideal class of drug delivery nanocarriers. The drugs can be physically encapsulated into void spaces or covalently bonded with functional groups on the surface [111].\nIn general, dendrimer-based drug nanocarriers, introduced in the early 1990s, had problems in the precise control of their drug release at the targeted region [112]. A solution to this limitation is to develop stimuli-responsive dendrimers. Zhu et al. introduced pH-responsive cis-aconityl bond between doxorubicin anticancer drug and PEGylated polyamidoamine (PAMAM) dendrimers for targeted delivery [113]. Doxorubicin-conjugated dendrimers by cis-aconityl pH-cleavable bonds showed prolonged acid-triggered drug release with 5% and 60% of the total DOX over 96 h at pH 7.4 and 5.5, respectively. Moreover, it was confirmed that pHresponsive cis-aconityl bonds facilitated enhanced cellular uptake and tumor accumulation due to the effective drug release after cellular internalization of the dendrimer. Similarly, Guo et al. successfully designed thermosensitive codendrimers using PAMAM and oligoethylene dendron (PAMAM-co-OED) [114]. The lower critical solution temperature (LCST), the critical temperature below which the components of a mixture are miscible for all compositions, of PAMAM-co-OED codendrimers was 38.2 ◦C, which is\nhigher than normal tissue temperature. When codendrimers reach a cancerous tissue, their drug release rate can be controlled by localized heating, resulting in enhanced therapeutic efficacy [115]. Fig. 3f shows an example of a temperature-responsive dendrimer.\nThe presence of large numbers of terminal end units in the dendrimer networks enables them to achieve multifunctional abilities. Pu et al. immobilized targeting molecules (biotin) and antitumor drug doxorubicin on the surface of poly(l-glutamic acid) dendrimers with polyhedral oligomeric silsesquioxane cores via acid-cleavable hydrazone linkage [116]. In vitro and in vivo studies verified that drugs were released in a pH-dependent manner and doxorubicin-dendrimer conjugates had an enhanced tumor inhibition activity with lower systemic toxicity.\nAlthough significant improvements have been made in dendrimer-based nanocarriers, they are rarely used as drug delivery carriers due to the complexity in their synthesis process and the lack of mass production methods [117]. In addition, only small amounts of drugs or targeting moieties can be linked to the dendrimers without altering their properties, such as increased polydispersity and poor water solubility.\nGiven their biocompatiblity and low toxicity rates, polymeric nanomaterials have a huge market potential and a number of them have recently entered into clinical trials [118]. It is believed that the novel interdisciplinary approaches in chemistry, polymer physics, materials science, bioengineering, and nanotechnology will overcome current challenges and lead to their fast translation into the new clinical applications."
    }, {
      "heading" : "Lipid-based nanomaterials",
      "text" : "Liposomes are composed of an aqueous core surrounded by a phospholipid bilayer resulting in the formation of amphiphilic and thermodynamically stabilized vesicles [122]. They are mostly made up of single or multiple phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine, and phosphatidylglycerol along with a stabilizer, usually cholesterol, to increase their stability [123]. The use of lipid-based nanomaterials for drug delivery dates back to 1965 when Bangham et al. introduced the use of swollen phospholipid systems followed by the introduction of a variety of enclosed phospholipid bilayer structures, which were initially termed “bangosomes” and then “liposomes” [124]. Initially, liposomes were designed with aims such as improving permeation of hydrophilic drugs, protection of peptides/protein-based drugs against harsh conditions, improved bioavailability along with passive delivery of the molecules, and reduced toxicity and side effects to overcome different barriers faced by the drug molecules inside the complex in vivo environment [125,126]. The targeting ability and drug release rates of liposomes inside the body are dependent on the type of lipids and ligands used, as well as the size, lamellarity, and surface properties as outlined in Fig. 4."
    }, {
      "heading" : "Liposomal synthesis",
      "text" : "The basic structure of the liposomes is very simple and their drug loading efficacy is affected by the method of their synthesis. The properties of liposomes such as their size, stability, drug loading capacity, and release kinetics can be tuned by varying the bilayer composition and the cholesterol content. One of the most notable features of the liposomal systems is their ability to incorporate both hydrophilic and hydrophobic moieties and deliver them to the site of action through extravascular and vascular routes of administration [127,128]. Hydrophilic drugs are encapsulated in the aqueous core of the liposomes while lipophilic drugs are incorporated in the lipid bilayer and amphiphilic drugs are partitioned at the sur-\nface of the bilayers [129]. Liposome synthesis is very complex and involves strategies to avoid problems associated with synthesis, drug retention, release, and stability both in vitro and in vivo due to the composition and fluidic nature of the bilayer membrane and the bilayer sensitivity to temperature variations while interacting with blood components after administration and during long term storage resulting in cargo leakage [130,131]. Developing novel synthesis techniques to control size, lamellarity, and tunable surface properties improved the potential of liposomes as a promising delivery system. The very first generation of small-size unilamellar vesicles of 100-nm size, large unilamellar vesicles of 200–800 nm in diameter, and multilamellar vesicles with a diameter of 500 nm to 5 m consisting of multiple concentric bilayers, were synthesized in the early 1970s [132]. Since the late 1970s, methods such as electroformation, freeze-drying, hydration, and double emulsion processes were adopted to fabricate liposomes. Other techniques especially those based on microfluidics have been extensively developed. These techniques emerged in the late 1980s and include extrusion, double emulsion, droplet emulsion transfer, pulsed jetting, transient membrane ejection, and hydrodynamic focusing [133]. Among these, micro-hydrodynamic focusing was used to fabricate monodisperse liposomes with highly controllable size and encapsulation efficiency through the modulation of bufferorganic phase flow rate ratios [134]. Another recent advancement in microfluidic-based synthesis is the NanoAssemblr platform and the NanoAssemblr scale up platform, which can produce liposomes with high precision and reproducibility both at laboratory and clinical scales [135]."
    }, {
      "heading" : "Chemo-responsive liposomes",
      "text" : "Physicochemical properties of the drugs greatly influence their incorporation and retention inside liposomes, which also govern their release profiles [136]. Previously reported loading methods result in low encapsulation efficiency due to limited quantity of the aqueous core since it is difficult to incorporate hydrophilic drugs into a bilayer, which is similar to the cell membrane and thus restricts the permeability of hydrophilic molecules [137]. Similarly, highly lipophilic drugs such as paclitaxel were also difficult to incorporate into liposomes [138]. A transmembrane chemical potential gradient method was developed for overcoming the problems associated with drug loading. Ammonium sulfate-based chemical gradients were used to precipitate the drugs in the inner core of liposome which resulted in high encapsulation efficiency of the drug [139]. Since many of the existing drugs are weak bases by nature, this method greatly improved their loading efficiency. Drug retention was also improved either by selecting drugs that could precipitate inside the liposomes like doxorubicin, or by linking the drugs with polyanions, or by converting acidic drugs to weak basic pro-drugs that could easily be released inside the body."
    }, {
      "heading" : "Long-circulating liposomes",
      "text" : "Another major problem faced by the conventional liposomes is their short circulatory half-lives and rapid clearance from the systemic circulation by the mononuclear phagocytic system (MPS) in the liver and spleen or opsonization by plasma proteins [140,141]. MPS blocking through pre-dosing of empty liposomes, was a technique initially used to improve the circulatory half-life of liposomes [142–144]. Conventional delivery of liposomes relies on endocytic pathway that has certain shortcomings such as limited endosomal escape and slow degradation in lysosomes. Newer methods include the fusion between liposomes and the cell membrane. This is achieved by changing the types of phospholipids, for example, by incorporating egg phosphatidylcholine and sphingomyelin and the addition of cholesterol to the liposome structure. Long-circulating\nliposomes coated with PEG chains were first described by Allen and Chonn in 1987 [145]. Depending on the length and density of PEG chains over the surface of the liposome, the circulatory half-life of the liposomes can be modified, resulting in the formation of sterically stable or stealth liposomes. These stealth liposomes proved their practical application in the treatment of Kaposi’s sarcoma in HIV patients [146]."
    }, {
      "heading" : "Targeted liposomes",
      "text" : "The use of liposomes functionalized with targeting moieties that can adhere to the cells of interest has been extensively explored. Among these targeting moieties, antibodies, folic acid or folates, and transferrin have shown promising applications as they are capable of binding to target cell receptors for targeted delivery for cancer treatment, since many tumor cells overexpress folate and transferrin receptors [147]. In other studies, antibodylabeled liposomes capable of crossing the blood brain barrier and targeting brain tumors as well as peptide-labeled liposomes for anti-angiogenic activity were developed to avoid tumor growth and metastasis [148,149]. Also, macrophage-targeting liposomes for cardiac repair after myocardial infarction, lymphatic drug delivery and treatment against infectious diseases have also been successfully fabricated.\nTherapeutic outcomes of liposomal drug delivery could be improved, if the release is triggered by some intrinsic mechanism or from an external source when they reach the target site. This remote triggering is beneficial in cancer treatment based on various local triggers available at or inside the tumor site. Various triggering mechanisms showing improved outcomes have been investigated and reported. These mechanisms can be classified as physiology-dependent such as pH or enzyme concentration/s and external stimuli-dependent (such as light, temperature, magnetic field, and ultrasound). The use of pH-sensitive liposomes dates back to 1984 [150]. They were designed to release their cargo in acidic\nenvironments around tumors where the pH drops to around 5.0. These liposomes were also used for delivery in acidic environment of endocytic vesicles. Enzyme-sensitive liposomes rely on the presence of specific enzymes at tumor or inflammation sites. Enzymes such as phospholipase and alkaline phosphatase destabilize the lipid bilayer, resulting in the release of the cargo. Thermo-sensitive liposomes were initially introduced by Yatvin and Weinstein in 1978 [151]. These liposomes have a phase transition temperature (TM) below which they are in gel state and stable while they go through fluid phase when the temperature becomes higher than TM, which occurs around 41–42 ◦C.\nLiposomes have also been designed for combination therapy either by simultaneous co-release or sequential independent release of multiple drugs loaded inside. In one particular work, transforming growth factor-ˇ (TGF-ˇ) inhibitor and interleukin-2 (IL-2) were co-loaded in liposomes and were gradually released over 7 days, which significantly delayed tumor growth and increased the survival time of tumor bearing mice [152]. The new generation of liposomes were designed to provide multimodal imaging as well as controlled drug release. Li et al. fabricated a multifunctional liposomal system loaded with doxorubicin, which could be imaged by MRI, NIR fluorescence, positron emission tomography (PET), and single photon emission computed tomography (SPECT) [153].\nEnveloped liposomes have been developed for increasing the stability of liposomes with improved oral pharmacokinetics and pharmacodynamics along with targeted delivery of anticancer drugs. Liposomes are enveloped with polymeric coats to achieve these aims through oral routes, ocular administration, and intranasal drug delivery.\nMost recently, attempts have been made to overcome the immunogenicity related to different nanoparticles by cloaking them with cell membranes of human blood components such as white blood cells (WBCs), red blood cells (RBCs), as well as platelets,\nto synthesize biomimetic cloaked nanoparticles or liposome-like vesicles, “leukosomes” [52,154]."
    }, {
      "heading" : "FDA approval and clinical trials",
      "text" : "Over the last three decades, researchers have been actively exploring the field of nanomedicine to improve the current standard of therapeutics. The rapid progress in the field stems from the immense potential of these nanoparticles to increase the drug abundance at the target site, decrease systemic toxicity, improve drug solubility, and as imaging and contrast agents along with various other clinical advantages. This active development in nanomedicine also demands sustained clinical translation and commercialization of these technologies, currently regulated by the FDA. Over the past two decades, the FDA has approved numerous nanomaterial-based drugs for clinical translation and over 200 new products are in clinical studies. In this section, we discuss the formulation and evolution over the years of those nanomaterials that have passed these regulations and have made it to the commercial market for human use (Table 1).\nCompositions of the nanomaterial-based drug play a vital role in their FDA approval. Based on the constituents of these clinically approved nanomedicine and consistency with the abovementioned divisions in this review, we can categorize them as (i) inorganic, (ii) polymeric, and (iii) liposomal. Polymeric and liposome-based nanomaterials have been a major component of the nanomaterial-based drugs in clinical translation with highest FDA approvals. However, over the last decade several inorganic nanomaterial-based drugs, which include nanocrystals and IONPs, have also been clinically approved. We discuss their current status and translation in the following section."
    }, {
      "heading" : "Inorganic nanomaterials",
      "text" : "Inorganic nanomaterials play a vital role in therapeutics for iron deficiency and as contrast agents in imaging. SPIONs have been a core component of inorganic nanomedicine [159]. Feridex (1996), GastroMARK (2001), and Feraheme (2009) are polymercoated SPIONs that were FDA-approved as MRI contrast-enhancers for imaging of cancers. However, in 2008 Feridex and in 2012 GastroMARK were withdrawn due to cytotoxicity [155].\nIONPs have also been used for sustained release of iron to replenish deficiency in anemia patients. These nanomedicines have been coated with biodegradable polymers, which allows increased biocompatibility and sustained degradation of the iron core for the treatment of anemia. Dextran-coated SPIONs, Feraheme, approved in 2009 by FDA has been used for the treatment of anemia and chronic kidney disease [160].\nIONPs have long been explored for use in cancer therapy due to their paramagnetic property and use as hyperthermia agents in alternating magnetic fields. NanoTherm, 15-nm SPIONs coated with aminosilane, has been recently approved in Europe for selective ablation of glioblastoma and has entered clinical trials in US for localized ablation of prostate cancer [161]. AuroLase is under phase I trial for thermal ablation of metastatic lung tumors. It consists of PEGylated gold-silica nanoshell that is optically active in the NIR region of the spectrum [162]. Recently, Hafnium oxide nanoparticles, NBTXR3, under phase II/III trials, has also shown utility in treating squamous cell carcinoma by electromagnetic radiation-induced cell death when injected locally [163]. The field of inorganic nanomedicine has shown some promising advancements with multiple formulations under clinical trials for cancer diagnostics, and photodynamic therapy of tumor as contrast agents."
    }, {
      "heading" : "Polymer-based nanomaterials",
      "text" : "Polymers have been an important constituent of clinically available nanomaterials. The varied use of polymeric nanomaterials can be associated with the tunability of chemically and biologically derived polymers. In the section on polymeric nanomaterials, we have classified polymeric nanomedicine into various categories and discussed their properties based on their chemical and biological moieties.\nAmongst polymers, PEG has been extensively used for conjugation with various proteins and peptides. PEGylation of the biological drugs has resulted in a tremendous increase in the stability of biologics, reduced immunogenicity, and prolonged circulation times. Adagen, a PEGylated adenosine deaminase enzyme was the first FDA-approved PEGylated drug in 1990 for severe combined immunodeficiency disease [164]. Over the last three decades, FDA has approved numerous PEGylated biologics for treating various diseases. Amongst these, Neulasta (2002), a PEGylated granulocyte-stimulating factor, has been very successful in the clinic for febrile neutropenia [165]. Recently, Plegridy (2014) and Adynovate (2015) have been FDA-approved and are PEGylated biologics for the treatment of multiple sclerosis (MS) and hemophilia, respectively [166,167]. The field has been continuously progressing with researchers considering more polymers to further increase the stability and half-life of the biologics. For example, zwitterionic polymers have shown promising results over PEG but the research in the field is still in its early stages.\nDegradable biopolymers have also shown success in clinical translation over the years. Copaxone, a random polypeptide consisting of l-glutamate, l-lysine, l-alanine, and l-tyrosine with a MW of ∼6.4 kDa, was FDA-approved in 1996 for MS. In 2002, FDA approved Eligard, which consists of Leuprolide acetate and PLGA, for prostate cancer treatment [156]. Currently, Opaxio, a biodegradable conjugate of paclitaxel and polyglutamic acid is under clinical phase III trial for drug delivery to head and neck cancer and has been approved for the status of infant drug by FDA [168]. Another paclitaxel-based PEG-co-PLA nanomedicine is under phase III trial, Genexol-PM, has shown lower toxicity in the treatment of nonsmall cell lung cancer (NSCLC) and metastatic breast cancer [169]. CRLX-101, a cyclodextrin-conjugated camptothecin, is under clinical phase I/II trial for rectal cancer [170]. New targeted polymeric nanomaterials are also being introduced into clinical trials. BIND014, which constitutes of docetaxel entrapped within a polymeric hydrophobic core and a PEGylated shell that also incorporates prostate-specific membrane antigen moieties, entered phase II/III trials for targeted drug delivery to NSCLC [171].\nProtein-drug conjugated nanomedicines have also come up as novel biodegradable delivery vehicles in contrast to chemically synthesized polymers. Abraxane, an albumin-paclitaxel nanoconjugate was approved by FDA in 2005 for efficient drug delivery to breast cancer [172]. This nanoconjugate was shown to have improved drug solubility and efficient tumor delivery. Recently, Abraxane has been approved for treatments of NSCLC (2012) and for late stage pancreatic cancer (2014) [173]. Currently, pharmaceutical companies have been actively working in the field of protein conjugated nanotherapeutics and their primary focus is towards composition and method of administration of the nanomedicine. Recently, ABI-009 entered phase II trials, another albumin-based nanoparticle but bound to rapamycin for treating bladder cancer and cancers with mTOR mutation [174]."
    }, {
      "heading" : "Liposomes",
      "text" : "As discussed earlier, liposomes are phospholipid bilayers that serve as a boundary between inner and outer aqueous phase. They have been used as carriers of either encapsulated hydrophilic\ndrugs in the inner aqueous core or hydrophobic drugs entrapped in the phospholipid bilayer. Due to their ability to shield chemically toxic drugs from undesirable effects and reduce their systemic toxicity, they have had tremendous success in clinical trials. Currently, several liposome-based nanomedicine formulations have been approved by FDA, as described below.\nLiposomal nanomaterials have made an important contribution in cancer therapy and in the treatment of some infectious diseases. FDA approved AmBisome in 1997, which consists of Amphotericin B encapsulated in the liposome for treatment of fungal infections [175]. Arikace, another actively pursued liposome-cloaked Amikacin, is a potent antibiotic for treatment of multidrug resistant gram-negative bacteria. This inhalable nanomedicine completed phase II clinical trials for the treatment of cystic fibrosis patients with pseudomonas lung infection and is actively pursued for approval from the FDA for non-tuberculous mycobacterial lung disease [176].\nLiposomal nanomedicine has also been shown to improve the pharmacokinetics of the encapsulated drugs along with an enhanced accumulation of drug near a solid tumor. These properties of liposome-based nanomedicines can be attributed to the biofunctionalization of liposome with PEG, which increases their circulation time and allows them to be retained near solid tumors having poor lymphatic drainage − which is attributed to enhanced permeability and retention (EPR) near the tumor site [127]. After Doxil, a PEGylated liposome-based cancer therapeutic introduced in 1995, the field of nanomedicine was actively pursued, which resulted in the subsequent approval of DaunoXome (1996), DepoCyt (1996), Marqibo (2012), and recently approved Onivyde (2015).\nThe limiting factor in the approval of nanomaterial-based drugs has been their passive targeting abilities based on EPR. As we further understand the physicochemical properties of these nan-\notherapeutics, active targeting-based nanomedicine has shown promising results in clinical studies. Currently, human epidermal growth factor receptor 2 (HER2)-targeted liposomal nanomedicine MM-302 (Merrimack Pharmaceuticals) is under clinical phase II/III trials. These liposomes are expected to show improved efficacy towards HER2-positive breast cancer and further improve the drug efficacy [177]. MBP-426 and SGT53, other nanotherapeutic agents under clinical phase I/II trials, are assumed to bind to transferrin receptor (TfR) for active targeting of liposomal encapsulated Oxaliplatin and wild-type p53 DNA, respectively [178]. Another liposomal nanomedicine under clinical phase III trial is ThermoDOX, which is a stimuli-responsive and thermosensitive drug delivery vehicle for treatment of hepatocellular carcinoma [179]. These trials will reinforce the need to improve active targeting of liposomal nanomedicines to gain improved drug efficacy and decrease the systemic toxicity of the drug. In a new approach Celator pharmaceuticals is considering combinatorial nanomedicine with CPX-351 under phase III trial. This drug is a synergistic combination of cytarabine and daunorubicin encapsulated in liposome for treatment of acute myeloid leukemia [180]."
    }, {
      "heading" : "Challenges in clinical approvals",
      "text" : "Although many nanomaterial-based drugs have been approved by the FDA, the success rate is not as one would expect. The number is not impressive because the development of methods and standard protocols required for their efficacy, toxicity, and safety testing for clinical use is still in need of standardization [181]. Without accepted scientific approaches for assessing safety, translation of nanomaterial-based therapeutics may prove challenging. There is a need of a systematic approach for nanoparticle synthesis, material optimization, screening, and identification of novel drug targets\nto maximize nanomaterials gaining successful clinical translation and ultimately an FDA approval.\nA substantial amount of time and effort has been invested by researchers over the years towards development of protocols where reproducible batches of nanoparticles can be synthesized consistently. The inability to translate nanomedicine platforms from academic reports to industrial scaling processes that comply with GMP and regulatory contexts for human use is still a challenge [182]. Several techniques, including particle replication in non-wetting template (PRINT) [183] and coaxial turbulent jet mixer [184] have been introduced in the market, promising efficient bulk nanoparticle synthesis. There is still a need for more robust technologies that could further help in large-scale production, which would support clinical translations.\nIn addition, controlling in vivo nanoparticle biodistribution and targeted delivery has posed a major challenge in their clinical translation. Fig. 5 shows recent developments in screening and assessing biodistribution of barcoded nanoparticles in vivo by Dahlman et al. [185]. Such studies are expected to provide insight on organ distribution of nanoparticles and potentially pave the path towards faster drug trials. Also, the development of organon-a-chip platforms, which are biomimetic in vitro models of their human counterparts, in evaluating pharmacokinetics and pharmacodynamics of nanoparticles in pre-clinical trials is an evolving field and will help significantly in toxicity studies of nanoparticle-based therapeutics [186]."
    }, {
      "heading" : "Conclusions",
      "text" : "The field of nanomedicine has brought forth many exciting new platforms for drug delivery. In addition to inorganic and polymeric nanomaterials, liposome-based nanotherapeutics have garnered much interest over the last few decades for excellent delivery of drugs, proteins, and genetic materials. Numerous nanomaterialbased novel methods have evolved over time for improving the successful clinical translation against plethora of diseases ranging from cancer to genetic disorders. Tremendous amount of scientific and clinical data is currently available and well understood over the years to build a core foundation for optimal design of nanomaterials to tune their biophysicochemical characteristics.\nWe believe that the future of nanomedicine lies in advancing multicomponent nanomaterials that target different pathologies at the same time. In most cases, there are complications associated with a chronic disease. It will be an important move forward to have universal nanomedicine platforms that address the main disease together with the medical complications associated with the same. Also, with the introduction of novel stimuli-responsive nanomaterials [187], we envision similar products in the market that will release the encapsulated drugs on demand. Another area that we feel the field might also benefit from is the design of particles that enable a dynamic control over their biodegradation after being introduced into the human body. Moreover, an area of interest that has not seen much progress in the last two decades is drug targeting across the blood-brain barrier (BBB). We foresee conjugation of nanomaterials with novel chemical groups or stimuli-responsive materials to enhance the BBB crossing to address treatment options for various neuronal diseases. In the upcoming years, we also believe the use of nanoparticles to deliver gene-editing tools (e.g. CRISPR/Cas9) [188] safely into cells to be properly established and used efficiently. In addition, organ-on-a-chip systems will likely help expedite interaction, efficacy, and toxicology studies of nanomaterials before going for in vivo investigations or clinical trials [186,189].\nIn the near future, we expect an increase in the FDA approvals of nanomedicines for human use. Although researchers have explored\nmany unconventional strategies including discovery of new drug targets and mechanisms, rapid nanomedicine screening, combinatorial therapy, and immunotherapy and immune-modulation along with functionalization of various antibodies and targeting moieties, there is still a lacuna in terms of new approvals from FDA. The current research in nanomedicine not only calls for new ideas but also demands researchers to consider long term and structured approach to pave way for successful clinical translation and fast FDA approval. The recommendations put forward by HofmanAmtenbrink et al. [182] are expected to expedite FDA approvals that will result in an increased footprint of nanomaterials in the pharmaceutical market."
    }, {
      "heading" : "Acknowledgments",
      "text" : "The authors acknowledge funding from the National Institutes of Health (AR057837, DE021468, D005865, AR068258, AR066193, EB022403, EB021148, R01EB024403) and the Presidential Early Career Award for Scientists and Engineers (PECASE). Y.S.Z. acknowledges the National Cancer Institute of the National Institutes of Health Pathway to Independence Award (K99CA201603). The authors further acknowledge funding from Swiss National Science Foundation (SNSF) to S.H., TUBITAK – Turkey to A.B.O., Henri Benedictus postdoctoral fellowship from Belgian American Educational Foundation (BAEF) and King Baudouin Foundation (KBS) to S.S."
    } ],
    "references" : [ {
      "title" : "Mater",
      "author" : [ "F.J. Heiligtag", "M. Niederberger" ],
      "venue" : "Today 16 ",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Gold Bull",
      "author" : [ "I. Freestone", "N. Meeks", "M. Sax", "C. Higgitt" ],
      "venue" : "40 ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "The technology of mesopotamian ceramic glazes",
      "author" : [ "D.V. Hill", "R.J. Speakman", "M.D. Glascock", "H. Neff" ],
      "venue" : "ACS Symp. Ser. ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Nat",
      "author" : [ "A. Sandhu" ],
      "venue" : "Nanotechnol. 1 ",
      "citeRegEx" : "5",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Biotechnol",
      "author" : [ "P.L. Gourley" ],
      "venue" : "Prog. 21 ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Curr",
      "author" : [ "D.S. Spencer", "A.S. Puranik", "N.A. Peppas" ],
      "venue" : "Opin. Chem. Eng. 7 ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nat",
      "author" : [ "G.M. Lanza" ],
      "venue" : "Nanotechnol. 10 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Y",
      "author" : [ "H. Chen", "B. Li", "X. Ren", "S. Li", "Y. Ma", "S. Cui" ],
      "venue" : "Gu, Biomaterials 33 ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Adv",
      "author" : [ "S.R. Shin", "Y.-C. Li", "H.L. Jang", "P. Khoshakhlagh", "M. Akbari", "A. Nasajpour", "Y.S. Zhang", "A. Tamayol", "A. Khademhosseini" ],
      "venue" : "Drug Deliv. Rev. 105 (Part B) ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Adv",
      "author" : [ "J. Nam", "N. Won", "J. Bang", "H. Jin", "J. Park", "S. Jung", "S. Jung", "Y. Park", "S. Kim" ],
      "venue" : "Drug Deliv. Rev. 65 ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Adv",
      "author" : [ "F.F. Davis" ],
      "venue" : "Drug Deliv. Rev. 54 ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "F",
      "author" : [ "M. Liong", "J. Lu", "M. Kovochich", "T. Xia", "S.G. Ruehm", "A.E. Nel" ],
      "venue" : "Tamanoi, J.I. Zink, ACS Nano 2 ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Colloidal Gold: Principles",
      "author" : [ "M.A. Hayat" ],
      "venue" : "Methods, and Applications, Academic Press, San Diego",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 1989
    }, {
      "title" : "Nano Lett",
      "author" : [ "A.S. Thakor", "J. Jokerst", "C. Zavaleta", "T.F. Massoud", "S.S. Gambhir" ],
      "venue" : "11 ",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Ther",
      "author" : [ "E.C. Dreaden", "L.A. Austin", "M.A. Mackey", "M.A. El-Sayed" ],
      "venue" : "Deliv. 3 ",
      "citeRegEx" : "17",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Nano Lett",
      "author" : [ "B.D. Chithrani", "A.A. Ghazani", "W.C. Chan" ],
      "venue" : "6 ",
      "citeRegEx" : "18",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Chem",
      "author" : [ "R. Mout", "D.F. Moyano", "S. Rana", "V.M. Rotello" ],
      "venue" : "Soc. Rev. 41 ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Discuss",
      "author" : [ "J. Turkevich", "P.C. Stevenson", "J. Hillier" ],
      "venue" : "Faraday Soc. ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 1951
    }, {
      "title" : "S",
      "author" : [ "S.R. Perala" ],
      "venue" : "Kumar, Langmuir 29 ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Acc",
      "author" : [ "A.C. Templeton", "W.P. Wuelfing", "R.W. Murray" ],
      "venue" : "Chem. Res. 33 ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2000
    }, {
      "title" : "M",
      "author" : [ "D.F. Moyano", "K. Saha", "G. Prakash", "B. Yan", "H. Kong" ],
      "venue" : "Yazdani, V.M. Rotello, ACS Nano 8 ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Proc",
      "author" : [ "C.H. Choi", "C.A. Alabi", "P. Webster", "M.E. Davis" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 107 ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Eur",
      "author" : [ "S. Hirn", "M. Semmler-Behnke", "C. Schleh", "A. Wenk", "J. Lipka", "M. Schaffler", "S. Takenaka", "W. Moller", "G. Schmid", "U. Simon", "W.G. Kreyling" ],
      "venue" : "J. Pharm. Biopharm. 77 ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "K",
      "author" : [ "F. Perche", "Y. Yi", "L. Hespel", "P. Mi", "A. Dirisala", "H. Cabral", "K. Miyata" ],
      "venue" : "Kataoka, Biomaterials 90 ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Sci",
      "author" : [ "L. Gamrad", "C. Rehbock", "A.M. Westendorf", "J. Buer", "S. Barcikowski", "W. Hansen" ],
      "venue" : "Rep. 6 ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Biomater",
      "author" : [ "L. Kong", "J. Qiu", "W. Sun", "J. Yang", "M. Shen", "L. Wang", "X. Shi" ],
      "venue" : "Sci. 5 ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Nano Res",
      "author" : [ "M. Yu", "B. Lei", "C. Gao", "J. Yan", "P.X. Ma" ],
      "venue" : "10 (2016) 49–63.  104  S. Hassan et al. / Nano Today 15 ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "C",
      "author" : [ "R. Tang", "C.S. Kim", "D.J. Solfiell", "S. Rana", "R. Mout", "E.M. Velazquez-Delgado", "A. Chompoosor", "Y. Jeong", "B. Yan", "Z.J. Zhu" ],
      "venue" : "Kim, J.A. Hardy, V.M. Rotello, ACS Nano 7 ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Bioconj",
      "author" : [ "M. Ray", "R. Tang", "Z.W. Jiang", "V.M. Rotello" ],
      "venue" : "Chem. 26 ",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "K",
      "author" : [ "R. Mout", "M. Ray", "G. Yesilbag Tonga", "Y.-W. Lee", "T. Tay" ],
      "venue" : "Sasaki, V.M. Rotello, ACS Nano 11 ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Chem",
      "author" : [ "E. Boisselier", "D. Astruc" ],
      "venue" : "Soc. Rev. 38 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Chem",
      "author" : [ "S.J. Oldenburg", "R.D. Averitt", "S.L. Westcott", "N.J. Halas" ],
      "venue" : "Phys. Lett. 288 ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 1998
    }, {
      "title" : "Acc",
      "author" : [ "S. Lal", "S.E. Clare", "N.J. Halas" ],
      "venue" : "Chem. Res. 41 ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Nanotechnol",
      "author" : [ "S. Hassan", "A.V. Singh", "J. Nanosci" ],
      "venue" : "14 ",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Eur",
      "author" : [ "K.J. Widder", "P.A. Marino", "R.M. Morris", "D.P. Howard", "G.A. Poore", "A.E. Senyei" ],
      "venue" : "J. Cancer Clin. Oncol. 19 ",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 1983
    }, {
      "title" : "Cancer Res",
      "author" : [ "A.S. Lubbe", "C. Bergemann", "W. Huhnt", "T. Fricke", "H. Riess", "J.W. Brock", "D. Huhn" ],
      "venue" : "56 ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "Cancer Lett",
      "author" : [ "P.B. Santhosh", "N.P. Ulrih" ],
      "venue" : "336 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nanoscale Res",
      "author" : [ "A. Akbarzadeh", "M. Samiei", "S. Davaran" ],
      "venue" : "Lett. 7 ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Chem",
      "author" : [ "S. Laurent", "D. Forge", "M. Port", "A. Roch", "C. Robic", "L. Vander Elst", "R.N. Muller" ],
      "venue" : "Rev. 108 ",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Int",
      "author" : [ "A. Jordan", "P. Wust", "H. Fahling", "W. John", "A. Hinz", "R. Felix" ],
      "venue" : "J. Hyperthermia 9 ",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 1993
    }, {
      "title" : "C",
      "author" : [ "A. Espinosa", "R. Di Corato", "J. Kolosnjaj-Tabi", "P. Flaud", "T. Pellegrino" ],
      "venue" : "Wilhelm, ACS Nano 10 ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nano Lett",
      "author" : [ "C. Xu", "D. Miranda-Nieves", "J.A. Ankrum", "M.E. Matthiesen", "J.A. Phillips", "I. Roes", "G.R. Wojtkiewicz", "V. Juneja", "J.R. Kultima", "W. Zhao", "P.K. Vemula", "C.P. Lin", "M. Nahrendorf", "J.M. Karp" ],
      "venue" : "12 ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Chem",
      "author" : [ "S.J. Soenen", "W.J. Parak", "J. Rejman", "B. Manshian" ],
      "venue" : "Rev. 115 ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Sci",
      "author" : [ "U. Sakulkhu", "M. Mahmoudi", "L. Maurizi", "J. Salaklang", "H. Hofmann" ],
      "venue" : "Rep. 4 ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Nat",
      "author" : [ "S. Zanganeh", "G. Hutter", "R. Spitler", "O. Lenkov", "M. Mahmoudi", "A. Shaw", "J.S. Pajarinen", "H. Nejadnik", "S. Goodman", "M. Moseley", "L.M. Coussens", "H.E. Daldrup-Link" ],
      "venue" : "Nanotechnol. 11 ",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Nat",
      "author" : [ "O. Veiseh", "B.C. Tang", "K.A. Whitehead", "D.G. Anderson", "R. Langer" ],
      "venue" : "Rev. Drug Discov. 14 ",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Y",
      "author" : [ "Y. Gao", "Y. Chen", "X. Ji", "X. He", "Q. Yin", "Z. Zhang", "J. Shi" ],
      "venue" : "Li, ACS Nano 5 ",
      "citeRegEx" : "50",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Acc",
      "author" : [ "J.E. Lee", "N. Lee", "T. Kim", "J. Kim", "T. Hyeon" ],
      "venue" : "Chem. Res. 44 ",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "N",
      "author" : [ "A. Parodi" ],
      "venue" : "Quattrocchi, A.L. van de Ven, C. Chiappini, M. Evangelopoulos, J.O. Martinez, B.S. Brown, S.Z. Khaled, I.K. Yazdi, M.V. Enzo, L. Isenhart, M. Ferrari, E. Tasciotti, Nat. Nanotechnol. 8 ",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "J",
      "author" : [ "W. Stober", "A. Fink", "E. Bohn" ],
      "venue" : "Colloid Interface Sci. 26 ",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 1968
    }, {
      "title" : "Chem",
      "author" : [ "C.Y. Lai", "B.G. Trewyn", "D.M. Jeftinija", "K. Jeftinija", "S. Xu", "S. Jeftinija", "V.S. Lin", "J. Am" ],
      "venue" : "Soc. 125 ",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Adv",
      "author" : [ "I.I. Slowing", "J.L. Vivero-Escoto", "C.-W. Wu", "V.S.Y. Lin" ],
      "venue" : "Drug Deliv. Rev. 60 ",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Nat",
      "author" : [ "S.E. Kim", "L. Zhang", "K. Ma", "M. Riegman", "F. Chen", "I. Ingold", "M. Conrad", "M.Z. Turker", "M. Gao", "X. Jiang", "S. Monette", "M. Pauliah", "M. Gonen", "P. Zanzonico", "T. Quinn", "U. Wiesner", "M.S. Bradbury", "M. Overholtzer" ],
      "venue" : "Nanotechnol. 11 ",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Phys",
      "author" : [ "L.E. Brus", "J. Chem" ],
      "venue" : "80 ",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 1984
    }, {
      "title" : "S",
      "author" : [ "X. Michalet", "F. Pinaud", "L. Bentolila", "J. Tsay", "S. Doose", "J. Li", "G. Sundaresan", "A. Wu", "S. Gambhir" ],
      "venue" : "Weiss, Science 307 ",
      "citeRegEx" : "59",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Colloids Surf",
      "author" : [ "X. He", "N. Ma" ],
      "venue" : "B 124 ",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Annu",
      "author" : [ "A.P. Alivisatos", "W. Gu", "C. Larabell" ],
      "venue" : "Rev. Biomed. Eng. 7 ",
      "citeRegEx" : "61",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Autoimmune Dis",
      "author" : [ "A.V. Singh", "M. Khare", "W.N. Gade", "P. Zamboni" ],
      "venue" : "2012 ",
      "citeRegEx" : "62",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Mater",
      "author" : [ "X. Cai", "Y. Luo", "W. Zhang", "D. Du", "Y. Lin", "ACS Appl" ],
      "venue" : "Interfaces 8 ",
      "citeRegEx" : "63",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "K.T. Yong", "W.C. Law", "R. Hu", "L. Ye", "L. Liu", "M.T. Swihart", "P.N. Prasad" ],
      "venue" : "Soc. Rev. 42 ",
      "citeRegEx" : "64",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nat",
      "author" : [ "E. Oh", "R. Liu", "A. Nel", "K.B. Gemill", "M. Bilal", "Y. Cohen", "I.L. Medintz" ],
      "venue" : "Nanotechnol. 11 ",
      "citeRegEx" : "65",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "G. Xu", "S. Zeng", "B. Zhang", "M.T. Swihart", "K.T. Yong", "P.N. Prasad" ],
      "venue" : "Rev. 116 ",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "J",
      "author" : [ "C.M. Johnson", "K.M. Pate", "Y. Shen", "A. Viswanath", "R. Tan", "B.C. Benicewicz", "M.A. Moss", "A.B. Greytak" ],
      "venue" : "Colloid Interface Sci. 458 ",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Chem",
      "author" : [ "D. Deng", "Y. Chen", "J. Cao", "J. Tian", "Z. Qian", "S. Achilefu", "Y. Gu" ],
      "venue" : "Mater. 24 ",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "L",
      "author" : [ "C.-M.J. Hu", "R.H. Fang", "B.T. Luk" ],
      "venue" : "Zhang, Nanoscale 6 ",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Biomater",
      "author" : [ "S. Kaur", "C. Prasad", "B. Balakrishnan", "R. Banerjee" ],
      "venue" : "Sci. 3 ",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nat",
      "author" : [ "R. Duncan" ],
      "venue" : "Rev. Drug Discov. 2 ",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Nat",
      "author" : [ "R. Duncan" ],
      "venue" : "Rev. Cancer 6 ",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "Trends Biotechnol",
      "author" : [ "M.J. Vicent", "R. Duncan" ],
      "venue" : "24 ",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2006
    }, {
      "title" : "J",
      "author" : [ "X. Pang", "Y. Jiang", "Q. Xiao", "A.W. Leung", "H. Hua", "C. Xu" ],
      "venue" : "Control. Release 222 ",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "X",
      "author" : [ "W. Wang", "B. Wang", "X. Ma", "S. Liu", "X. Shang" ],
      "venue" : "Yu, Biomacromolecules 17 ",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Y",
      "author" : [ "Y. Wu", "D. Zhou", "Q. Zhang", "Z. Xie", "X. Chen", "X. Jing" ],
      "venue" : "Huang, Biomacromolecules 17 ",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Int",
      "author" : [ "J. Kreuter" ],
      "venue" : "J. Pharm. 331 ",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "J",
      "author" : [ "R. Langer" ],
      "venue" : "Folkman, Nature 263 ",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 1976
    }, {
      "title" : "Proc",
      "author" : [ "Y. Cao", "R. Langer" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 105 ",
      "citeRegEx" : "80",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Drug Discov",
      "author" : [ "M. Cagel", "E. Grotz", "E. Bernabeu", "M.A. Moretton", "D.A. Chiappetta" ],
      "venue" : "Today 22 ",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "J",
      "author" : [ "F. Danhier", "E. Ansorena", "J.M. Silva", "R. Coco", "A. Le Breton", "V. Préat" ],
      "venue" : "Control. Release 161 ",
      "citeRegEx" : "82",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Polym",
      "author" : [ "F. Alexis" ],
      "venue" : "Int. 54 ",
      "citeRegEx" : "83",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Colloids Surf",
      "author" : [ "Q. Gan", "T. Wang" ],
      "venue" : "B 59 ",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Adv",
      "author" : [ "Z. Liu", "Y. Jiao", "Y. Wang", "C. Zhou", "Z. Zhang" ],
      "venue" : "Drug Deliv. Rev. 60 ",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "J",
      "author" : [ "S.A. Agnihotri", "N.N. Mallikarjuna", "T.M. Aminabhavi" ],
      "venue" : "Control. Release 100 ",
      "citeRegEx" : "86",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Expert Opin",
      "author" : [ "P. Rajitha", "D. Gopinath", "R. Biswas", "M. Sabitha", "R. Jayakumar" ],
      "venue" : "Drug Deliv. ",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chitin and Chitosan for Regenerative Medicine",
      "author" : [ "P.K. Dutta" ],
      "venue" : "New Book Series: Composite Polymer Material, Springer",
      "citeRegEx" : "88",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Acta Biomater",
      "author" : [ "J. Wu", "C. Tang", "C. Yin" ],
      "venue" : "47 ",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Angew",
      "author" : [ "H. Bader", "H. Ringsdorf", "B. Schmidt" ],
      "venue" : "Makromol. Chem. 123 ",
      "citeRegEx" : "90",
      "shortCiteRegEx" : null,
      "year" : 1984
    }, {
      "title" : "Acta Biomater",
      "author" : [ "C.-C. Cheng", "F.-C. Chang", "W.-Y. Kao", "S.-M. Hwang", "L.-C. Liao", "Y.-J. Chang", "M.-C. Liang", "J.-K. Chen", "D.-J. Lee" ],
      "venue" : "33 ",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Mater",
      "author" : [ "J. Mao", "Y. Li", "T. Wu", "C. Yuan", "B. Zeng", "Y. Xu", "L. Dai", "ACS Appl" ],
      "venue" : "Interfaces 8 ",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Sci",
      "author" : [ "Z. Xu", "S. Liu", "Y. Kang", "M. Wang", "ACS Biomater" ],
      "venue" : "Eng. 1 ",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Polym",
      "author" : [ "M. Huo", "J. Yuan", "L. Tao", "Y. Wei" ],
      "venue" : "Chem. 5 ",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Int",
      "author" : [ "C. Chang", "H. Wei", "D.-Q. Wu", "B. Yang", "N. Chen", "S.-X. Cheng", "X.-Z. Zhang", "R.-X. Zhuo" ],
      "venue" : "J. Pharm. 420 ",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Nat",
      "author" : [ "J.E. Chung", "S. Tan", "S.J. Gao", "N. Yongvongsoontorn", "S.H. Kim", "J.H. Lee", "H.S. Choi", "H. Yano", "L. Zhuo", "M. Kurisawa", "J.Y. Ying" ],
      "venue" : "Nanotechnol. 9 ",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Angew",
      "author" : [ "A.V. Kabanov", "S.V. Vinogradov" ],
      "venue" : "Chem. Int. Ed. 48 ",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "C",
      "author" : [ "H.-Q. Wu" ],
      "venue" : "Wang, Langmuir 32 ",
      "citeRegEx" : "101",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "J",
      "author" : [ "W. Chen", "Y. Hou", "Z. Tu", "L. Gao", "R. Haag" ],
      "venue" : "Control. Release 16 ",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "J",
      "author" : [ "K.S. Soni", "S.S. Desale", "T.K. Bronich" ],
      "venue" : "Control. Release 240 ",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Mater",
      "author" : [ "S. Jin", "J. Wan", "L. Meng", "X. Huang", "J. Guo", "L. Liu", "C. Wang", "ACS Appl" ],
      "venue" : "Interfaces 7 ",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Wiley Interdiscip",
      "author" : [ "M. Karimi", "M. Eslami", "P. Sahandi-Zangabad", "F. Mirab", "N. Farajisafiloo", "Z. Shafaei", "D. Ghosh", "M. Bozorgomid", "F. Dashkhaneh", "M.R. Hamblin" ],
      "venue" : "Rev. Nanomed. Nanobiotechnol. 8 ",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Angew",
      "author" : [ "T. Sun", "Y.S. Zhang", "B. Pang", "D.C. Hyun", "M. Yang", "Y. Xia" ],
      "venue" : "Chem. Int. Ed. 53 ",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Angew",
      "author" : [ "J.Z. Du", "T.M. Sun", "W.J. Song", "J. Wu", "J. Wang" ],
      "venue" : "Chem. Int. Ed. 49 ",
      "citeRegEx" : "107",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Biochem",
      "author" : [ "D.A. Tomalia", "L. Reyna", "S. Svenson" ],
      "venue" : "Soc. Trans. 35 ",
      "citeRegEx" : "108",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Drug Discov",
      "author" : [ "R. Esfand", "D.A. Tomalia" ],
      "venue" : "Today 6 ",
      "citeRegEx" : "109",
      "shortCiteRegEx" : null,
      "year" : 2001
    }, {
      "title" : "Drug Discov",
      "author" : [ "E.R. Gillies", "J.M. Frechet" ],
      "venue" : "Today 10 ",
      "citeRegEx" : "110",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "J",
      "author" : [ "H.J. Hsu" ],
      "venue" : "Bugno, S.r. Lee, S. Hong, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 9 ",
      "citeRegEx" : "111",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Sci",
      "author" : [ "Y. Zhao", "Y. Guo", "R. Li", "T. Wang", "M. Han", "C. Zhu", "X. Wang" ],
      "venue" : "Rep. 6 ",
      "citeRegEx" : "112",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Y",
      "author" : [ "S. Zhu", "M. Hong", "G. Tang", "L. Qian", "J. Lin", "Y. Jiang" ],
      "venue" : "Pei, Biomaterials 31 ",
      "citeRegEx" : "113",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Bioconj",
      "author" : [ "Y. Guo", "Y. Zhao", "J. Zhao", "M. Han", "A. Zhang", "X. Wang" ],
      "venue" : "Chem. 25 ",
      "citeRegEx" : "114",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "J",
      "author" : [ "J.E. Chung", "M. Yokoyama", "M. Yamato", "T. Aoyagi", "Y. Sakurai", "T. Okano" ],
      "venue" : "Control. Release 62 ",
      "citeRegEx" : "115",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "Z",
      "author" : [ "Y. Pu", "S. Chang", "H. Yuan", "G. Wang", "B. He" ],
      "venue" : "Gu, Biomaterials 34 ",
      "citeRegEx" : "116",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Biomedical Engineering: Frontier Research and Converging Technologies",
      "author" : [ "H. Jo", "H.-W. Jun", "J. Shin", "S. Lee" ],
      "venue" : "Springer",
      "citeRegEx" : "117",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Targeted Drug Delivery: Concepts and Design",
      "author" : [ "P.V. Devarajan", "S. Jain" ],
      "venue" : "Springer",
      "citeRegEx" : "118",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Sci",
      "author" : [ "Y. Zhang", "C. Yang", "W. Wang", "J. Liu", "Q. Liu", "F. Huang", "L. Chu", "H. Gao", "C. Li", "D. Kong" ],
      "venue" : "Rep. 6 ",
      "citeRegEx" : "119",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Am",
      "author" : [ "G. Suffredini", "J. East", "L.M. Levy" ],
      "venue" : "J. Neuroradiol. 35 ",
      "citeRegEx" : "120",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Biomater",
      "author" : [ "H. Wang", "Q. Huang", "H. Chang", "J. Xiao", "Y. Cheng" ],
      "venue" : "Sci. 4 ",
      "citeRegEx" : "121",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Trends Biotechnol",
      "author" : [ "G. Gregoriadis" ],
      "venue" : "13 ",
      "citeRegEx" : "122",
      "shortCiteRegEx" : null,
      "year" : 1995
    }, {
      "title" : "Chem",
      "author" : [ "B.S. Pattni", "V.V. Chupin", "V.P. Torchilin" ],
      "venue" : "Rev. 115 ",
      "citeRegEx" : "123",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "FASEB J",
      "author" : [ "D.W. Deamer" ],
      "venue" : "24 ",
      "citeRegEx" : "124",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Nat",
      "author" : [ "V.P. Torchilin" ],
      "venue" : "Rev. Drug Discov. 4 ",
      "citeRegEx" : "125",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Chem",
      "author" : [ "Y.P. Patil", "S. Jadhav" ],
      "venue" : "Phys. Lipids 177 ",
      "citeRegEx" : "126",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Adv",
      "author" : [ "T.M. Allen", "P.R. Cullis" ],
      "venue" : "Drug Deliv. Rev. 65 ",
      "citeRegEx" : "127",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Drug Discov",
      "author" : [ "M. Slingerland", "H.-J. Guchelaar", "H. Gelderblom" ],
      "venue" : "Today 17 ",
      "citeRegEx" : "128",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Int",
      "author" : [ "G. Bozzuto", "A. Molinari" ],
      "venue" : "J. Nanomed. 10 ",
      "citeRegEx" : "130",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Proc",
      "author" : [ "A. Gabizon", "D. Papahadjopoulos" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 85 (1988) 6949–6953.  S. Hassan et al. / Nano Today 15 ",
      "citeRegEx" : "131",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Proc",
      "author" : [ "G. Weissmann", "D. Bloomgarden", "R. Kaplan", "C. Cohen", "S. Hoffstein", "T. Collins", "A. Gotlieb", "D. Nagle" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 72 ",
      "citeRegEx" : "132",
      "shortCiteRegEx" : null,
      "year" : 1975
    }, {
      "title" : "Sci",
      "author" : [ "D. Carugo", "E. Bottaro", "J. Owen", "E. Stride", "C. Nastruzzi" ],
      "venue" : "Rep. 6 ",
      "citeRegEx" : "133",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Chem",
      "author" : [ "A. Jahn", "W.N. Vreeland", "M. Gaitan", "L.E. Locascio", "J. Am" ],
      "venue" : "Soc. 126 ",
      "citeRegEx" : "134",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Chem",
      "author" : [ "T.A. Balbino", "N.T. Aoki", "A.A. Gasperini", "C.L. Oliveira", "A.R. Azzoni", "L.P. Cavalcanti", "G. Lucimara" ],
      "venue" : "Eng. J. 226 ",
      "citeRegEx" : "135",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "J",
      "author" : [ "D. Zucker", "D. Marcus", "Y. Barenholz", "A. Goldblum" ],
      "venue" : "Control. Release 139 ",
      "citeRegEx" : "136",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Expert Opin",
      "author" : [ "J. Gubernator" ],
      "venue" : "Drug Deliv. 8 ",
      "citeRegEx" : "137",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "J",
      "author" : [ "S. Koudelka", "J. Turanek" ],
      "venue" : "Control. Release 163 ",
      "citeRegEx" : "138",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Biochim",
      "author" : [ "D. Lasic", "B. Čeh", "M. Stuart", "L. Guo", "P. Frederik", "Y. Barenholz" ],
      "venue" : "Biophys. Acta 1239 ",
      "citeRegEx" : "139",
      "shortCiteRegEx" : null,
      "year" : 1995
    }, {
      "title" : "Adv",
      "author" : [ "R.L. Juliano" ],
      "venue" : "Drug Deliv. Rev. 2 ",
      "citeRegEx" : "140",
      "shortCiteRegEx" : null,
      "year" : 1988
    }, {
      "title" : "Biosci",
      "author" : [ "T. Ishida", "H. Harashima", "H. Kiwada" ],
      "venue" : "Rep. 22 ",
      "citeRegEx" : "141",
      "shortCiteRegEx" : null,
      "year" : 2002
    }, {
      "title" : "J",
      "author" : [ "E. Afergan", "H. Epstein", "R. Dahan", "N. Koroukhov", "K. Rohekar", "H.D. Danenberg", "G. Golomb" ],
      "venue" : "Control. Release 132 ",
      "citeRegEx" : "143",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Biochim",
      "author" : [ "J.N. Verma", "N.M. Wassef", "R.A. Wirtz", "C.T. Atkinson", "M. Aikawa", "L.D. Loomis", "C.R. Alving" ],
      "venue" : "Biophys. Acta 1066 ",
      "citeRegEx" : "144",
      "shortCiteRegEx" : null,
      "year" : 1991
    }, {
      "title" : "FEBS Lett",
      "author" : [ "T. Allen", "A. Chonn" ],
      "venue" : "223 ",
      "citeRegEx" : "145",
      "shortCiteRegEx" : null,
      "year" : 1987
    }, {
      "title" : "Biol",
      "author" : [ "F. Cainelli", "A. Vallone" ],
      "venue" : "Targets Ther. 3 ",
      "citeRegEx" : "146",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Bioavailab",
      "author" : [ "X. Wang", "W. Lu", "J. Bioequiv" ],
      "venue" : "8 ",
      "citeRegEx" : "147",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Int",
      "author" : [ "A. Janssen", "R. Schiffelers", "T. Ten Hagen", "G. Koning", "A. Schraa", "R. Kok", "G. Storm", "G. Molema" ],
      "venue" : "J. Pharm. 254 ",
      "citeRegEx" : "148",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Int",
      "author" : [ "D.B. Vieira", "L.F. Gamarra" ],
      "venue" : "J. Nanomed. 11 ",
      "citeRegEx" : "149",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Proc",
      "author" : [ "J. Connor", "M.B. Yatvin", "L. Huang" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 81 ",
      "citeRegEx" : "150",
      "shortCiteRegEx" : null,
      "year" : 1984
    }, {
      "title" : "R",
      "author" : [ "M.B. Yatvin", "J.N. Weinstein", "W.H. Dennis" ],
      "venue" : "Blumenthal, Science 202 ",
      "citeRegEx" : "151",
      "shortCiteRegEx" : null,
      "year" : 1978
    }, {
      "title" : "Nat",
      "author" : [ "J. Park", "S.H. Wrzesinski", "E. Stern", "M. Look", "J. Criscione", "R. Ragheb", "S.M. Jay", "S.L. Demento", "A. Agawu", "P.L. Limon" ],
      "venue" : "Mater. 11 ",
      "citeRegEx" : "152",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Bioconjug",
      "author" : [ "S. Li", "B. Goins", "L. Zhang", "A. Bao" ],
      "venue" : "Chem. 23 ",
      "citeRegEx" : "153",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Proc",
      "author" : [ "C.-M.J. Hu", "L. Zhang", "S. Aryal", "C. Cheung", "R.H. Fang", "L. Zhang" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 108 ",
      "citeRegEx" : "154",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "AAPS J",
      "author" : [ "A.C. Anselmo", "S. Mitragotri" ],
      "venue" : "17 ",
      "citeRegEx" : "155",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Polym",
      "author" : [ "S.N.S. Alconcel", "A.S. Baas", "H.D. Maynard" ],
      "venue" : "Chem. 2 ",
      "citeRegEx" : "156",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "J",
      "author" : [ "M.L. Etheridge", "S.A. Campbell", "A.G. Erdman", "C.L. Haynes", "S.M. Wolf" ],
      "venue" : "McCullough, Nanomedicine 9 ",
      "citeRegEx" : "157",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nat",
      "author" : [ "J. Shi", "P.W. Kantoff", "R. Wooster", "O.C. Farokhzad" ],
      "venue" : "Rev. Cancer 17 ",
      "citeRegEx" : "158",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "Adv",
      "author" : [ "C. Sun", "J.S. Lee", "M. Zhang" ],
      "venue" : "Drug Deliv. Rev. 60 ",
      "citeRegEx" : "159",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Am",
      "author" : [ "M. Lu", "M.H. Cohen", "D. Rieves", "R. Pazdur" ],
      "venue" : "J. Hematol. 85 ",
      "citeRegEx" : "160",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "J",
      "author" : [ "K. Maier-Hauff", "F. Ulrich", "D. Nestler", "H. Niehoff", "P. Wust", "B. Thiesen", "H. Orawa", "V. Budach", "A. Jordan" ],
      "venue" : "Neurooncol. 103 ",
      "citeRegEx" : "161",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Proc",
      "author" : [ "L.R. Hirsch", "R.J. Stafford", "J.A. Bankson", "S.R. Sershen", "B. Rivera", "R.E. Price", "J.D. Hazle", "N.J. Halas", "J.L. West" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 100 ",
      "citeRegEx" : "162",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Future Oncol",
      "author" : [ "L. Maggiorella", "G. Barouch", "C. Devaux", "A. Pottier", "E. Deutsch", "J. Bourhis", "E. Borghi", "L. Levy" ],
      "venue" : "8 ",
      "citeRegEx" : "163",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Curr",
      "author" : [ "M. Vellard" ],
      "venue" : "Opin. Biotechnol. 14 ",
      "citeRegEx" : "164",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "Cell",
      "author" : [ "M. Ing", "N. Gupta", "M. Teyssandier", "B. Maillere", "M. Pallardy", "S. Delignat", "S. Lacroix-Desmazes", "A. Consortium" ],
      "venue" : "Immunol. 301 ",
      "citeRegEx" : "166",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Pharmacol",
      "author" : [ "X. Hu", "L. Miller", "S. Richman", "S. Hitchman", "G. Glick", "S. Liu", "Y. Zhu", "M. Crossman", "I. Nestorov", "R.S. Gronke", "D.P. Baker", "M. Rogge", "M. Subramanyam", "G. Davar", "J. Clin" ],
      "venue" : "52 ",
      "citeRegEx" : "167",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Expert Opin Investig",
      "author" : [ "V.L. Galic", "J.D. Wright", "S.N. Lewin", "T.J. Herzog" ],
      "venue" : "Drugs 20 ",
      "citeRegEx" : "168",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Cancer Chemother",
      "author" : [ "H.K. Ahn", "M. Jung", "S.J. Sym", "D.B. Shin", "S.M. Kang", "S.Y. Kyung", "J.W. Park", "S.H. Jeong", "E.K. Cho" ],
      "venue" : "Pharmacol. 74 ",
      "citeRegEx" : "169",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Ann",
      "author" : [ "S.M. Keefe", "J. Hoffman-Censits", "R.B. Cohen", "R. Mamtani", "D. Heitjan", "S. Eliasof", "A. Nixon", "B. Turnbull", "E.G. Garmey", "O. Gunnarsson", "M. Waliki", "J. Ciconte", "L. Jayaraman", "A. Senderowicz", "A.B. Tellez", "M. Hennessy", "A. Piscitelli", "D. Vaughn", "A. Smith", "N.B. Haas" ],
      "venue" : "Oncol. 27 ",
      "citeRegEx" : "170",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Int",
      "author" : [ "E. Miele", "G.P. Spinelli", "E. Miele", "F. Tomao", "S. Tomao" ],
      "venue" : "J. Nanomed. 4 ",
      "citeRegEx" : "172",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "J",
      "author" : [ "M.W. Saif" ],
      "venue" : "O. P 14 ",
      "citeRegEx" : "173",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Oncol",
      "author" : [ "J.M. McKiernan", "D. Lascano", "J. Ahn", "R. Ghandour", "J.S. Pak", "A. RoyChoudhury", "S. Chang", "G.J. DeCastro", "N. Desai", "J. Clin" ],
      "venue" : "33 ",
      "citeRegEx" : "174",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "J",
      "author" : [ "T.J. Walsh", "R.W. Finberg", "C. Arndt", "J. Hiemenz", "C. Schwartz", "D. Bodensteiner", "P. Pappas", "N. Seibel", "R.N. Greenberg", "S. Dummer", "M. Schuster", "J.S. Holcenberg", "N. Engl" ],
      "venue" : "Med. 340 ",
      "citeRegEx" : "175",
      "shortCiteRegEx" : null,
      "year" : 1999
    }, {
      "title" : "G",
      "author" : [ "J.P. Clancy", "L. Dupont", "M.W. Konstan", "J. Billings", "S. Fustik", "C.H. Goss", "J. Lymp", "P. Minic", "A.L. Quittner", "R.C. Rubenstein", "K.R. Young", "L. Saiman", "J.L. Burns", "J.R. Govan", "B. Ramsey", "R. Gupta" ],
      "venue" : "Arikace Study, Thorax 68 ",
      "citeRegEx" : "176",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Mol",
      "author" : [ "E. Geretti", "S.C. Leonard", "N. Dumont", "H. Lee", "J. Zheng", "R. De Souza", "D.F. Gaddy", "C.W. Espelin", "D.A. Jaffray", "V. Moyo", "U.B. Nielsen", "T.J. Wickham", "B.S. Hendriks" ],
      "venue" : "Cancer Ther. 14 ",
      "citeRegEx" : "177",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Cancer Gene Ther",
      "author" : [ "E.R. Camp", "C. Wang", "E.C. Little", "P.M. Watson", "K.F. Pirollo", "A. Rait", "D.J. Cole", "E.H. Chang", "D.K. Watson" ],
      "venue" : "20 ",
      "citeRegEx" : "178",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "M",
      "author" : [ "J.E. Lancet", "J.E. Cortes", "D.E. Hogge", "M.S. Tallman", "T.J. Kovacsovics", "L.E. Damon", "R. Komrokji", "S.R. Solomon", "J.E. Kolitz" ],
      "venue" : "Cooper, A.M. Yeager, A.C. Louie, E.J. Feldman, Blood 123 ",
      "citeRegEx" : "180",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "J",
      "author" : [ "D.W. Grainger", "Y.H. Bae" ],
      "venue" : "Control. Release 220 ",
      "citeRegEx" : "181",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nanomed",
      "author" : [ "M. Hofmann-Amtenbrink", "D.W. Grainger", "H. Hofmann" ],
      "venue" : "Nanotechnol. Biol. Med.",
      "citeRegEx" : "182",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Angew",
      "author" : [ "J. Xu", "D.H. Wong", "J.D. Byrne", "K. Chen", "C. Bowerman", "J.M. DeSimone" ],
      "venue" : "Chem. Int. Ed. Engl. 52 ",
      "citeRegEx" : "183",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "R",
      "author" : [ "J.M. Lim", "A. Swami", "L.M. Gilson", "S. Chopra", "S. Choi", "J. Wu", "R. Langer" ],
      "venue" : "Karnik, O.C. Farokhzad, ACS Nano 8 ",
      "citeRegEx" : "184",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Proc",
      "author" : [ "J.E. Dahlman", "K.J. Kauffman", "Y. Xing", "T.E. Shaw", "F.F. Mir", "C.C. Dlott", "R. Langer", "D.G. Anderson", "E.T. Wang" ],
      "venue" : "Natl. Acad. Sci. U. S. A. 114 ",
      "citeRegEx" : "185",
      "shortCiteRegEx" : null,
      "year" : 2017
    }, {
      "title" : "J",
      "author" : [ "N.S. Bhise", "J. Ribas", "V. Manoharan", "Y.S. Zhang", "A. Polini", "S. Massa", "M.R. Dokmeci", "A. Khademhosseini" ],
      "venue" : "Control. Release 190 ",
      "citeRegEx" : "186",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chem",
      "author" : [ "C.J. Carling", "M.L. Viger", "V.A. Huu", "A.V. Garcia", "A. Almutairi" ],
      "venue" : "Sci. 6 ",
      "citeRegEx" : "187",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Nat",
      "author" : [ "B.T. Staahl", "M. Benekareddy", "C. Coulon-Bainier", "A.A. Banfal", "S.N. Floor", "J.K. Sabo", "C. Urnes", "G.A. Munares", "A. Ghosh", "J.A. Doudna" ],
      "venue" : "Biotechnol. 35 ",
      "citeRegEx" : "188",
      "shortCiteRegEx" : null,
      "year" : 2017
    } ],
    "referenceMentions" : [ {
      "referenceID" : 0,
      "context" : "As early as 2500 BC, natural asbestos was used to increase the reinforcement of a ceramic mixture for decorative purposes [1].",
      "startOffset" : 122,
      "endOffset" : 125
    }, {
      "referenceID" : 1,
      "context" : "The famous Lycurgus cup made by the Romans in the 4th century AD displayed different colors during the day and when illuminated from inside at night [2].",
      "startOffset" : 149,
      "endOffset" : 152
    }, {
      "referenceID" : 2,
      "context" : "Mesopotamians in the 9th century AD introduced silver and/or copper glazed ceramics [3].",
      "startOffset" : 84,
      "endOffset" : 87
    }, {
      "referenceID" : 3,
      "context" : "It was not until the famous statement, “there is plenty of room at the bottom” from Feynman in 1959 [4] that brought nanotechnology back into focus of the modern scientific world and exactly a decade after, the term “nanotechnology” was coined [5].",
      "startOffset" : 244,
      "endOffset" : 247
    }, {
      "referenceID" : 4,
      "context" : "drug delivery, tissue engineering, targeted drug delivery, bio-microelectromechanical systems (bioMEMS), biosensors, microfluidics, and diagnostics [6].",
      "startOffset" : 148,
      "endOffset" : 151
    }, {
      "referenceID" : 5,
      "context" : "Due to the extraordinary opportunity it offers, nanomaterial-based drug delivery has emerged as the mainstream application of nanotechnology in medicine [7].",
      "startOffset" : 153,
      "endOffset" : 156
    }, {
      "referenceID" : 6,
      "context" : "Nanomaterials in medicine have been traditionally used for drug delivery applications only; however, new nanoscale platforms have been developed that offer a diagnostic application in addition to their therapeutic ability [9].",
      "startOffset" : 222,
      "endOffset" : 225
    }, {
      "referenceID" : 7,
      "context" : "Multifunctional nanomaterials have been developed that combine therapeutic, targeting, and imaging capabilities for advanced drug delivery systems and are gaining increasing attention from the research community [10].",
      "startOffset" : 212,
      "endOffset" : 216
    }, {
      "referenceID" : 8,
      "context" : "Carbon-based nanomaterials for biomedical and tissue engineering applications have been discussed elsewhere [11].",
      "startOffset" : 108,
      "endOffset" : 112
    }, {
      "referenceID" : 9,
      "context" : "effective imaging and contrast agents [12].",
      "startOffset" : 38,
      "endOffset" : 42
    }, {
      "referenceID" : 10,
      "context" : "polyethylene glycol conjugation (PEGylation) [13], charge modulation, ligand conjugation, and inclusion of stimuli-responsive",
      "startOffset" : 45,
      "endOffset" : 49
    }, {
      "referenceID" : 11,
      "context" : "moieties and small-molecule probes for improved drug efficacy [14].",
      "startOffset" : 62,
      "endOffset" : 66
    }, {
      "referenceID" : 12,
      "context" : "Michael Faraday in 1850 [15], where through synthesis he showed the ability to obtain a ruby red colloidal solution of AuNPs from yel-",
      "startOffset" : 24,
      "endOffset" : 28
    }, {
      "referenceID" : 13,
      "context" : "However, medicinal application of gold salt was not proposed until 1890, as bacteriostatic against tuberculosis [16].",
      "startOffset" : 112,
      "endOffset" : 116
    }, {
      "referenceID" : 13,
      "context" : "Subsequently, gold was also found to be effective in the treatment of Rheumatoid arthritis in 1927 [16].",
      "startOffset" : 99,
      "endOffset" : 103
    }, {
      "referenceID" : 17,
      "context" : "reducing agent for synthesis of AuNPs in 1951 [20].",
      "startOffset" : 46,
      "endOffset" : 50
    }, {
      "referenceID" : 18,
      "context" : "Shiffrin-Brust used thiols in biphasic solvent along with sodium borohydride and phase transfer reagents to yield 2–4 nm thiol-coated AuNPs [21].",
      "startOffset" : 140,
      "endOffset" : 144
    }, {
      "referenceID" : 19,
      "context" : "developed post-synthesis ligand substitution on AuNP surface [22].",
      "startOffset" : 61,
      "endOffset" : 65
    }, {
      "referenceID" : 20,
      "context" : "biophysicochemical interactions of these nanoparticles for low nonspecific protein adsorption [23], active targeting of the tumor [24], and enhanced cellular uptake [25].",
      "startOffset" : 94,
      "endOffset" : 98
    }, {
      "referenceID" : 21,
      "context" : "biophysicochemical interactions of these nanoparticles for low nonspecific protein adsorption [23], active targeting of the tumor [24], and enhanced cellular uptake [25].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 22,
      "context" : "biophysicochemical interactions of these nanoparticles for low nonspecific protein adsorption [23], active targeting of the tumor [24], and enhanced cellular uptake [25].",
      "startOffset" : 165,
      "endOffset" : 169
    }, {
      "referenceID" : 23,
      "context" : "modified the surface of PEGylated AuNPs with hydroxychloroquine for efficient endosomal escape and increased siRNA distribution [26].",
      "startOffset" : 128,
      "endOffset" : 132
    }, {
      "referenceID" : 27,
      "context" : "have reported the use of AuNPs-stabilized capsules (AuNPSCs) as an efficient protein delivery system [30].",
      "startOffset" : 101,
      "endOffset" : 105
    }, {
      "referenceID" : 28,
      "context" : "have demonstrated the versatility of the AuNPSCmediated delivery system by intracellular targeting of the proteins to the nucleus [31].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 29,
      "context" : "used programmed assembly of AuNPs with modified Cas9 protein for direct cytosolic delivery and efficient gene editing [32].",
      "startOffset" : 118,
      "endOffset" : 122
    }, {
      "referenceID" : 30,
      "context" : "Gold nanorods (AuNRs) have been quite extensively used for these applications as their length and width can be modulated to obtain SPR bands in the near-infrared (NIR) regions to allow better contrast in biological tissues [33].",
      "startOffset" : 223,
      "endOffset" : 227
    }, {
      "referenceID" : 31,
      "context" : "synthesized gold nanoshells (AuNSs) through silica nanoparticle-templated growth of gold, which have an absorption band in the NIR region and their optical properties can be tuned by controlling thickness of the gold coating [34].",
      "startOffset" : 225,
      "endOffset" : 229
    }, {
      "referenceID" : 32,
      "context" : "The photothermal property of the gold nanostructures also allows thermal ablation of solid tumors if the AuNSs are excited by NIR and they have shown promising results in clinical studies towards FDA approval under the name of AuroLase [35].",
      "startOffset" : 236,
      "endOffset" : 240
    }, {
      "referenceID" : 33,
      "context" : "Understanding of size, shape, and surface properties of AuNPs has culminated into various clinical trials as drug carriers and imaging agents; but a supplementary understanding of their cytotoxicity, bio-distribution, and clearance from the body is required for improving their clinical translation [36].",
      "startOffset" : 299,
      "endOffset" : 303
    }, {
      "referenceID" : 34,
      "context" : "in 1979, by encapsulating IONPs in albumin microspheres along with a chemotherapeutic agent to establish an in vivo delivery method [38].",
      "startOffset" : 132,
      "endOffset" : 136
    }, {
      "referenceID" : 35,
      "context" : "Since then encapsulated IONPs have been explored for site-specific delivery and entered Phase I clinical trial in 1996 for delivery of epirubicin for treatment of advanced cancer [39].",
      "startOffset" : 179,
      "endOffset" : 183
    }, {
      "referenceID" : 36,
      "context" : "surface modification, and (iv) contrast agent for magnetic resonance imaging (MRI) [40].",
      "startOffset" : 83,
      "endOffset" : 87
    }, {
      "referenceID" : 37,
      "context" : "These nanoparticles exhibit single-domain magnetic property in the sub-100 nm range, which has maximum coercivity as compared to the bulk magnetite that is multi-domain [41].",
      "startOffset" : 169,
      "endOffset" : 173
    }, {
      "referenceID" : 38,
      "context" : "When thermal energy equals the anisotropy energy, it results in random flipping of the magnetic moment and the nanoparticles exhibit super paramagnetic nature [42].",
      "startOffset" : 159,
      "endOffset" : 163
    }, {
      "referenceID" : 39,
      "context" : "These superparamagnetic IONPs (SPIONs) heat up when placed in an alternating electric field (hyperthermia) [43].",
      "startOffset" : 107,
      "endOffset" : 111
    }, {
      "referenceID" : 40,
      "context" : "synthesized 20-nm iron oxide nanocube, which were heated with alternating magnetic fields and NIR radiation to show complete ablation of solid tumor in vivo due to increased heating power that they termed as dual-mode activation [44].",
      "startOffset" : 229,
      "endOffset" : 233
    }, {
      "referenceID" : 41,
      "context" : "to track the MSCs post-engraftment [45].",
      "startOffset" : 35,
      "endOffset" : 39
    }, {
      "referenceID" : 42,
      "context" : "The rapid degradation of IONPs results in release of Fe2+/3+ ions that alters levels of ferritin, and inflammatory cytokines and several other reactive oxygen species (ROS)-dependent proteins in cells, increasing their cytotoxicity [46].",
      "startOffset" : 232,
      "endOffset" : 236
    }, {
      "referenceID" : 43,
      "context" : "Further, they found that electrostatic charge played an important role and the negatively charged PVA SPIONs had less protein adsorption (22%) compared to 36% and 41% on positive and neutral PVA-coated SPIONs [47].",
      "startOffset" : 209,
      "endOffset" : 213
    }, {
      "referenceID" : 44,
      "context" : "showed that Ferumtoxyl could polarize macrophages in tumor tissue to pro-inflammatory M1 phenotype, which could constrain the proliferation of subcutaneous adenocarcinomas [48].",
      "startOffset" : 172,
      "endOffset" : 176
    }, {
      "referenceID" : 44,
      "context" : "They also showed the tendency of the SPIONs to inhibit liver metastasis up to 6 times if Ferumtoxyl was pre-injected in vivo [48].",
      "startOffset" : 125,
      "endOffset" : 129
    }, {
      "referenceID" : 45,
      "context" : "SPIONs-based imaging has also been effective in distinguishing non-diabetic patients from the ones with recent onset of diabetes due to enhanced accumulation of SPIONs in pancreases [49]; this discovery led the way for drug delivery to pancreas for diabetes.",
      "startOffset" : 182,
      "endOffset" : 186
    }, {
      "referenceID" : 46,
      "context" : "SiNPs provide a new modality to the inorganic nanoparticles due to their rapid degradation in vivo, regulated pore sizes (2–10 nm) for drug encapsulation [50], incorporation of metals for theranostic applications [51], and ease of camouflage by chemical conjugations [52].",
      "startOffset" : 154,
      "endOffset" : 158
    }, {
      "referenceID" : 47,
      "context" : "SiNPs provide a new modality to the inorganic nanoparticles due to their rapid degradation in vivo, regulated pore sizes (2–10 nm) for drug encapsulation [50], incorporation of metals for theranostic applications [51], and ease of camouflage by chemical conjugations [52].",
      "startOffset" : 213,
      "endOffset" : 217
    }, {
      "referenceID" : 48,
      "context" : "SiNPs provide a new modality to the inorganic nanoparticles due to their rapid degradation in vivo, regulated pore sizes (2–10 nm) for drug encapsulation [50], incorporation of metals for theranostic applications [51], and ease of camouflage by chemical conjugations [52].",
      "startOffset" : 267,
      "endOffset" : 271
    }, {
      "referenceID" : 49,
      "context" : "proposed synthesis of solid SiNPs by a process based on hydrolysis in ammonium oxide of silyl ethers [53].",
      "startOffset" : 101,
      "endOffset" : 105
    }, {
      "referenceID" : 46,
      "context" : "The pore size of MSNPs can be modulated by using various templates, surfactant concentrations, pH, and solvents during the synthesis; this control allows sustained degradation of the particles to deliver various payloads [50].",
      "startOffset" : 221,
      "endOffset" : 225
    }, {
      "referenceID" : 50,
      "context" : "MSNPs have also been explored as stimuli-responsive drug release systems, where various chemical entities on the surface of MSNPs can be used to control the release of encapsulated drug by a trigger reaction [55].",
      "startOffset" : 208,
      "endOffset" : 212
    }, {
      "referenceID" : 48,
      "context" : "In the past years, various systems such as AuNPs, IONPs, CdS nanoparticles, and polymers have been used as gatekeepers for controlled release [52,56].",
      "startOffset" : 142,
      "endOffset" : 149
    }, {
      "referenceID" : 51,
      "context" : "In the past years, various systems such as AuNPs, IONPs, CdS nanoparticles, and polymers have been used as gatekeepers for controlled release [52,56].",
      "startOffset" : 142,
      "endOffset" : 149
    }, {
      "referenceID" : 48,
      "context" : "used advanced techniques to show enhanced delivery of doxorubicin using cell membranecloaked MSNPs [52].",
      "startOffset" : 99,
      "endOffset" : 103
    }, {
      "referenceID" : 53,
      "context" : "In the 1980s, researchers discovered that confined SiNPs emitted red light upon illumination with laser [58].",
      "startOffset" : 104,
      "endOffset" : 108
    }, {
      "referenceID" : 54,
      "context" : "They are crystalline in nature and comprise of two different periodic group elements with the size varying in the range of 2–10 nm [59].",
      "startOffset" : 131,
      "endOffset" : 135
    }, {
      "referenceID" : 57,
      "context" : "Over the years, QDs have been widely explored in theranostics alone and as an adjunct with wide variety of nanomaterials [62].",
      "startOffset" : 121,
      "endOffset" : 125
    }, {
      "referenceID" : 58,
      "context" : "used pH-responsive ZnO-QDs coordinated with doxorubicin for targeted drug delivery using hyaluronic acid conjugation [63].",
      "startOffset" : 117,
      "endOffset" : 121
    }, {
      "referenceID" : 59,
      "context" : "QDs have been explored for various applications in vitro and in vivo but they are yet to be approved in clinical trials due to their potential cytotoxicity [64].",
      "startOffset" : 156,
      "endOffset" : 160
    }, {
      "referenceID" : 60,
      "context" : "analyzed the published literature to elucidate the dominant role of surface properties and size of the QDs on the cytotoxicity [65].",
      "startOffset" : 127,
      "endOffset" : 131
    }, {
      "referenceID" : 61,
      "context" : "To minimize the cytotoxic effect, researchers are exploring Cd-free QDs [66], which have come up as less cytotoxic nanoparticles along with advances in more efficient polymeric coating of the QDs [67,68].",
      "startOffset" : 72,
      "endOffset" : 76
    }, {
      "referenceID" : 62,
      "context" : "To minimize the cytotoxic effect, researchers are exploring Cd-free QDs [66], which have come up as less cytotoxic nanoparticles along with advances in more efficient polymeric coating of the QDs [67,68].",
      "startOffset" : 196,
      "endOffset" : 203
    }, {
      "referenceID" : 63,
      "context" : "To minimize the cytotoxic effect, researchers are exploring Cd-free QDs [66], which have come up as less cytotoxic nanoparticles along with advances in more efficient polymeric coating of the QDs [67,68].",
      "startOffset" : 196,
      "endOffset" : 203
    }, {
      "referenceID" : 64,
      "context" : "Among various nanotherapeutics, polymeric nanoparticles stand out as a versatile class of nanocarriers that allow controlled drug delivery to diseased tissues [69].",
      "startOffset" : 159,
      "endOffset" : 163
    }, {
      "referenceID" : 65,
      "context" : "Third-generation polymeric nanocarriers are represented by multi-functionalities, such as targeting and multi-drug release properties [70].",
      "startOffset" : 134,
      "endOffset" : 138
    }, {
      "referenceID" : 66,
      "context" : "3a), are one of the most explored polymeric drug delivery platforms [71,72].",
      "startOffset" : 68,
      "endOffset" : 75
    }, {
      "referenceID" : 67,
      "context" : "3a), are one of the most explored polymeric drug delivery platforms [71,72].",
      "startOffset" : 68,
      "endOffset" : 75
    }, {
      "referenceID" : 68,
      "context" : "), which prevents undesirable drug release in blood circulation [73].",
      "startOffset" : 64,
      "endOffset" : 68
    }, {
      "referenceID" : 69,
      "context" : "Compared to the other conventional polymer-based platforms, these systems generally have enhanced stability, low toxicity, higher drug-loading capacity, and prolonged drug release behaviors [74].",
      "startOffset" : 190,
      "endOffset" : 194
    }, {
      "referenceID" : 70,
      "context" : "developed a new endosomal acid-stimulating polymer-drug conjugate platform, poly(2-(methacryloyloxy)ethyl choline phosphate)-b-poly(2-methoxy-2-oxoethyl methacrylatehydrazide doxorubicin) (PCP-DOX) [75].",
      "startOffset" : 198,
      "endOffset" : 202
    }, {
      "referenceID" : 110,
      "context" : "(a) Polymer-drug conjugates [119], (b) Polymeric",
      "startOffset" : 28,
      "endOffset" : 33
    }, {
      "referenceID" : 111,
      "context" : "nanoparticles [120], (c) A dual-pH-sensitive polymeric micelles from self-assembling of a block copolymer-doxorubicin conjugate [92] and (d) thermo-sensitive shelf-",
      "startOffset" : 14,
      "endOffset" : 19
    }, {
      "referenceID" : 86,
      "context" : "nanoparticles [120], (c) A dual-pH-sensitive polymeric micelles from self-assembling of a block copolymer-doxorubicin conjugate [92] and (d) thermo-sensitive shelf-",
      "startOffset" : 128,
      "endOffset" : 132
    }, {
      "referenceID" : 89,
      "context" : "crosslinked micelles [97], (e) FA- and PEG-functionalized nanogels for multi-drug delivery [104], and (f) thermo-responsive dendrimers [121].",
      "startOffset" : 21,
      "endOffset" : 25
    }, {
      "referenceID" : 95,
      "context" : "crosslinked micelles [97], (e) FA- and PEG-functionalized nanogels for multi-drug delivery [104], and (f) thermo-responsive dendrimers [121].",
      "startOffset" : 91,
      "endOffset" : 96
    }, {
      "referenceID" : 112,
      "context" : "crosslinked micelles [97], (e) FA- and PEG-functionalized nanogels for multi-drug delivery [104], and (f) thermo-responsive dendrimers [121].",
      "startOffset" : 135,
      "endOffset" : 140
    }, {
      "referenceID" : 112,
      "context" : "permissions from Royal Society of Chemistry for [121], Nature Publishing Group for [119], American Society of Neuroradiology for [120], American Chemical Society for [92] and",
      "startOffset" : 48,
      "endOffset" : 53
    }, {
      "referenceID" : 110,
      "context" : "permissions from Royal Society of Chemistry for [121], Nature Publishing Group for [119], American Society of Neuroradiology for [120], American Chemical Society for [92] and",
      "startOffset" : 83,
      "endOffset" : 88
    }, {
      "referenceID" : 111,
      "context" : "permissions from Royal Society of Chemistry for [121], Nature Publishing Group for [119], American Society of Neuroradiology for [120], American Chemical Society for [92] and",
      "startOffset" : 129,
      "endOffset" : 134
    }, {
      "referenceID" : 86,
      "context" : "permissions from Royal Society of Chemistry for [121], Nature Publishing Group for [119], American Society of Neuroradiology for [120], American Chemical Society for [92] and",
      "startOffset" : 166,
      "endOffset" : 170
    }, {
      "referenceID" : 71,
      "context" : "created a pH/reduction dual-responsive charge-conversional polymeric prodrug decorated with reduction-responsive disulfide units and acid-labile anticancer drugs for efficient co-delivery of doxorubicin and demethylcantharidin for effective cancer therapy [76].",
      "startOffset" : 256,
      "endOffset" : 260
    }, {
      "referenceID" : 72,
      "context" : "The concept of polymeric nanoparticles for the delivery of therapeutic agents was first proposed by Speiser and his team in 1969 [77].",
      "startOffset" : 129,
      "endOffset" : 133
    }, {
      "referenceID" : 75,
      "context" : "in biologic fluids after their administration [81].",
      "startOffset" : 46,
      "endOffset" : 50
    }, {
      "referenceID" : 76,
      "context" : "The greatest advantage of this polymer is that its properties, such as molecular weight, drug release rate, hydrophobicity, and biodegradability can be regulated by manipulating lactideto-glycolide (L:G) ratio [82].",
      "startOffset" : 210,
      "endOffset" : 214
    }, {
      "referenceID" : 77,
      "context" : "studied the effect of the L:G ratio variations from 70:30 to 90:10 on mitomycin-C release [83].",
      "startOffset" : 90,
      "endOffset" : 94
    }, {
      "referenceID" : 81,
      "context" : "The release of therapeutic agents from chitosan-based nanoparticles is dependent upon polymer erosion, polymer-drug interactions, and their swelling potential, which are affected by the pH of the medium [87,88].",
      "startOffset" : 203,
      "endOffset" : 210
    }, {
      "referenceID" : 82,
      "context" : "The release of therapeutic agents from chitosan-based nanoparticles is dependent upon polymer erosion, polymer-drug interactions, and their swelling potential, which are affected by the pH of the medium [87,88].",
      "startOffset" : 203,
      "endOffset" : 210
    }, {
      "referenceID" : 83,
      "context" : "designed recombinant human interleukin-2 (rhIL-2) and doxorubicin-loaded chitosan-based nanoparticles for the enhanced anticancer activity [89].",
      "startOffset" : 139,
      "endOffset" : 143
    }, {
      "referenceID" : 84,
      "context" : "in 1984 [90], have a spherical core-shell structure, which was formed via self-assembling of amphiphilic block copolymers in aqueous solutions.",
      "startOffset" : 8,
      "endOffset" : 12
    }, {
      "referenceID" : 85,
      "context" : "The hydrophobic core creates a cargo space for entrapment of hydrophobic therapeutic agents, whereas the hydrophilic shell protects the formed micelle against aggregation and prolongs circulation time in blood [91].",
      "startOffset" : 210,
      "endOffset" : 214
    }, {
      "referenceID" : 86,
      "context" : "developed a simple method to design a dual-pH-responsive nanocarrier platform from self-assembly of a block copolymer, poly(2-(diisopropylamino)-ethyl methacrylate-b-poly(4-formyl phenyl methacrylate-co-polyethylene glycol monomethyl ether methacrylate) (PDPA-b-P(FPMA-co-OEGMA)), that responds to two different pH values [92].",
      "startOffset" : 322,
      "endOffset" : 326
    }, {
      "referenceID" : 88,
      "context" : "In the presence of the ROS, copolymers can be converted into more hydrophilic components [95].",
      "startOffset" : 89,
      "endOffset" : 93
    }, {
      "referenceID" : 89,
      "context" : "To enhance their stability, chemical crosslinking of polymeric micelles has been developed by Ding and Liu in 1998 [97].",
      "startOffset" : 115,
      "endOffset" : 119
    }, {
      "referenceID" : 90,
      "context" : "introduced self-assembling micellar complexes conjugated with organic tea extracts for cancer therapy [99].",
      "startOffset" : 102,
      "endOffset" : 106
    }, {
      "referenceID" : 91,
      "context" : "Nanogels are hydrophilic or amphiphilic polymeric particles that absorb water and swell [100].",
      "startOffset" : 88,
      "endOffset" : 93
    }, {
      "referenceID" : 92,
      "context" : "They are physically or chemically crosslinked polymeric hydrogel networks with sizes of around 100–200 nm that show swelling behavior with high water-retaining capacity [101].",
      "startOffset" : 169,
      "endOffset" : 174
    }, {
      "referenceID" : 93,
      "context" : "Compared to other nanocarriers, nanogels possess several significant advantages, such as higher drug loading capacity, enhanced stability, control over particle size, larger surface area, and increased stimuli-responsiveness to pH, temperature, redox conductions, and enzymes [102,103].",
      "startOffset" : 276,
      "endOffset" : 285
    }, {
      "referenceID" : 94,
      "context" : "Compared to other nanocarriers, nanogels possess several significant advantages, such as higher drug loading capacity, enhanced stability, control over particle size, larger surface area, and increased stimuli-responsiveness to pH, temperature, redox conductions, and enzymes [102,103].",
      "startOffset" : 276,
      "endOffset" : 285
    }, {
      "referenceID" : 95,
      "context" : "synthesized new multi-stimuli-responsive nanogels, allowing for selective release of hydrophobic and hydrophilic drug molecules [104].",
      "startOffset" : 128,
      "endOffset" : 133
    }, {
      "referenceID" : 96,
      "context" : "Nanogel-based multi-stimuli-responsive dual-drug delivery platforms offer a great potential especially for combination chemotherapy [105].",
      "startOffset" : 132,
      "endOffset" : 137
    }, {
      "referenceID" : 97,
      "context" : "Nanogels can be easily converted from a negativelycharged state to a positively charged state in the tumor extracellular acidic conditions, which promotes the efficiency of drug release in the targeted area [106].",
      "startOffset" : 207,
      "endOffset" : 212
    }, {
      "referenceID" : 98,
      "context" : "developed drug-loaded acidsensitive charge conversional nanogels to promote drug release and cellular internalization triggered by the extracellular pH [107].",
      "startOffset" : 152,
      "endOffset" : 157
    }, {
      "referenceID" : 102,
      "context" : "The drugs can be physically encapsulated into void spaces or covalently bonded with functional groups on the surface [111].",
      "startOffset" : 117,
      "endOffset" : 122
    }, {
      "referenceID" : 103,
      "context" : "In general, dendrimer-based drug nanocarriers, introduced in the early 1990s, had problems in the precise control of their drug release at the targeted region [112].",
      "startOffset" : 159,
      "endOffset" : 164
    }, {
      "referenceID" : 104,
      "context" : "introduced pH-responsive cis-aconityl bond between doxorubicin anticancer drug and PEGylated polyamidoamine (PAMAM) dendrimers for targeted delivery [113].",
      "startOffset" : 149,
      "endOffset" : 154
    }, {
      "referenceID" : 105,
      "context" : "successfully designed thermosensitive codendrimers using PAMAM and oligoethylene dendron (PAMAM-co-OED) [114].",
      "startOffset" : 104,
      "endOffset" : 109
    }, {
      "referenceID" : 106,
      "context" : "When codendrimers reach a cancerous tissue, their drug release rate can be controlled by localized heating, resulting in enhanced therapeutic efficacy [115].",
      "startOffset" : 151,
      "endOffset" : 156
    }, {
      "referenceID" : 107,
      "context" : "immobilized targeting molecules (biotin) and antitumor drug doxorubicin on the surface of poly(l-glutamic acid) dendrimers with polyhedral oligomeric silsesquioxane cores via acid-cleavable hydrazone linkage [116].",
      "startOffset" : 208,
      "endOffset" : 213
    }, {
      "referenceID" : 108,
      "context" : "Although significant improvements have been made in dendrimer-based nanocarriers, they are rarely used as drug delivery carriers due to the complexity in their synthesis process and the lack of mass production methods [117].",
      "startOffset" : 218,
      "endOffset" : 223
    }, {
      "referenceID" : 109,
      "context" : "Given their biocompatiblity and low toxicity rates, polymeric nanomaterials have a huge market potential and a number of them have recently entered into clinical trials [118].",
      "startOffset" : 169,
      "endOffset" : 174
    }, {
      "referenceID" : 113,
      "context" : "Liposomes are composed of an aqueous core surrounded by a phospholipid bilayer resulting in the formation of amphiphilic and thermodynamically stabilized vesicles [122].",
      "startOffset" : 163,
      "endOffset" : 168
    }, {
      "referenceID" : 114,
      "context" : "They are mostly made up of single or multiple phospholipids such as phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine, and phosphatidylglycerol along with a stabilizer, usually cholesterol, to increase their stability [123].",
      "startOffset" : 244,
      "endOffset" : 249
    }, {
      "referenceID" : 115,
      "context" : "introduced the use of swollen phospholipid systems followed by the introduction of a variety of enclosed phospholipid bilayer structures, which were initially termed “bangosomes” and then “liposomes” [124].",
      "startOffset" : 200,
      "endOffset" : 205
    }, {
      "referenceID" : 116,
      "context" : "Initially, liposomes were designed with aims such as improving permeation of hydrophilic drugs, protection of peptides/protein-based drugs against harsh conditions, improved bioavailability along with passive delivery of the molecules, and reduced toxicity and side effects to overcome different barriers faced by the drug molecules inside the complex in vivo environment [125,126].",
      "startOffset" : 372,
      "endOffset" : 381
    }, {
      "referenceID" : 117,
      "context" : "Initially, liposomes were designed with aims such as improving permeation of hydrophilic drugs, protection of peptides/protein-based drugs against harsh conditions, improved bioavailability along with passive delivery of the molecules, and reduced toxicity and side effects to overcome different barriers faced by the drug molecules inside the complex in vivo environment [125,126].",
      "startOffset" : 372,
      "endOffset" : 381
    }, {
      "referenceID" : 118,
      "context" : "One of the most notable features of the liposomal systems is their ability to incorporate both hydrophilic and hydrophobic moieties and deliver them to the site of action through extravascular and vascular routes of administration [127,128].",
      "startOffset" : 231,
      "endOffset" : 240
    }, {
      "referenceID" : 119,
      "context" : "One of the most notable features of the liposomal systems is their ability to incorporate both hydrophilic and hydrophobic moieties and deliver them to the site of action through extravascular and vascular routes of administration [127,128].",
      "startOffset" : 231,
      "endOffset" : 240
    }, {
      "referenceID" : 120,
      "context" : "Liposome synthesis is very complex and involves strategies to avoid problems associated with synthesis, drug retention, release, and stability both in vitro and in vivo due to the composition and fluidic nature of the bilayer membrane and the bilayer sensitivity to temperature variations while interacting with blood components after administration and during long term storage resulting in cargo leakage [130,131].",
      "startOffset" : 406,
      "endOffset" : 415
    }, {
      "referenceID" : 121,
      "context" : "Liposome synthesis is very complex and involves strategies to avoid problems associated with synthesis, drug retention, release, and stability both in vitro and in vivo due to the composition and fluidic nature of the bilayer membrane and the bilayer sensitivity to temperature variations while interacting with blood components after administration and during long term storage resulting in cargo leakage [130,131].",
      "startOffset" : 406,
      "endOffset" : 415
    }, {
      "referenceID" : 122,
      "context" : "The very first generation of small-size unilamellar vesicles of 100-nm size, large unilamellar vesicles of 200–800 nm in diameter, and multilamellar vesicles with a diameter of 500 nm to 5 m consisting of multiple concentric bilayers, were synthesized in the early 1970s [132].",
      "startOffset" : 271,
      "endOffset" : 276
    }, {
      "referenceID" : 123,
      "context" : "These techniques emerged in the late 1980s and include extrusion, double emulsion, droplet emulsion transfer, pulsed jetting, transient membrane ejection, and hydrodynamic focusing [133].",
      "startOffset" : 181,
      "endOffset" : 186
    }, {
      "referenceID" : 124,
      "context" : "Among these, micro-hydrodynamic focusing was used to fabricate monodisperse liposomes with highly controllable size and encapsulation efficiency through the modulation of bufferorganic phase flow rate ratios [134].",
      "startOffset" : 208,
      "endOffset" : 213
    }, {
      "referenceID" : 125,
      "context" : "Another recent advancement in microfluidic-based synthesis is the NanoAssemblr platform and the NanoAssemblr scale up platform, which can produce liposomes with high precision and reproducibility both at laboratory and clinical scales [135].",
      "startOffset" : 235,
      "endOffset" : 240
    }, {
      "referenceID" : 126,
      "context" : "Physicochemical properties of the drugs greatly influence their incorporation and retention inside liposomes, which also govern their release profiles [136].",
      "startOffset" : 151,
      "endOffset" : 156
    }, {
      "referenceID" : 127,
      "context" : "Previously reported loading methods result in low encapsulation efficiency due to limited quantity of the aqueous core since it is difficult to incorporate hydrophilic drugs into a bilayer, which is similar to the cell membrane and thus restricts the permeability of hydrophilic molecules [137].",
      "startOffset" : 289,
      "endOffset" : 294
    }, {
      "referenceID" : 128,
      "context" : "Similarly, highly lipophilic drugs such as paclitaxel were also difficult to incorporate into liposomes [138].",
      "startOffset" : 104,
      "endOffset" : 109
    }, {
      "referenceID" : 129,
      "context" : "Ammonium sulfate-based chemical gradients were used to precipitate the drugs in the inner core of liposome which resulted in high encapsulation efficiency of the drug [139].",
      "startOffset" : 167,
      "endOffset" : 172
    }, {
      "referenceID" : 130,
      "context" : "Another major problem faced by the conventional liposomes is their short circulatory half-lives and rapid clearance from the systemic circulation by the mononuclear phagocytic system (MPS) in the liver and spleen or opsonization by plasma proteins [140,141].",
      "startOffset" : 248,
      "endOffset" : 257
    }, {
      "referenceID" : 131,
      "context" : "Another major problem faced by the conventional liposomes is their short circulatory half-lives and rapid clearance from the systemic circulation by the mononuclear phagocytic system (MPS) in the liver and spleen or opsonization by plasma proteins [140,141].",
      "startOffset" : 248,
      "endOffset" : 257
    }, {
      "referenceID" : 134,
      "context" : "liposomes coated with PEG chains were first described by Allen and Chonn in 1987 [145].",
      "startOffset" : 81,
      "endOffset" : 86
    }, {
      "referenceID" : 135,
      "context" : "These stealth liposomes proved their practical application in the treatment of Kaposi’s sarcoma in HIV patients [146].",
      "startOffset" : 112,
      "endOffset" : 117
    }, {
      "referenceID" : 136,
      "context" : "delivery for cancer treatment, since many tumor cells overexpress folate and transferrin receptors [147].",
      "startOffset" : 99,
      "endOffset" : 104
    }, {
      "referenceID" : 137,
      "context" : "anti-angiogenic activity were developed to avoid tumor growth and metastasis [148,149].",
      "startOffset" : 77,
      "endOffset" : 86
    }, {
      "referenceID" : 138,
      "context" : "anti-angiogenic activity were developed to avoid tumor growth and metastasis [148,149].",
      "startOffset" : 77,
      "endOffset" : 86
    }, {
      "referenceID" : 139,
      "context" : "The use of pH-sensitive liposomes dates back to 1984 [150].",
      "startOffset" : 53,
      "endOffset" : 58
    }, {
      "referenceID" : 140,
      "context" : "Thermo-sensitive liposomes were initially introduced by Yatvin and Weinstein in 1978 [151].",
      "startOffset" : 85,
      "endOffset" : 90
    }, {
      "referenceID" : 141,
      "context" : "increased the survival time of tumor bearing mice [152].",
      "startOffset" : 50,
      "endOffset" : 55
    }, {
      "referenceID" : 48,
      "context" : "to synthesize biomimetic cloaked nanoparticles or liposome-like vesicles, “leukosomes” [52,154].",
      "startOffset" : 87,
      "endOffset" : 95
    }, {
      "referenceID" : 143,
      "context" : "to synthesize biomimetic cloaked nanoparticles or liposome-like vesicles, “leukosomes” [52,154].",
      "startOffset" : 87,
      "endOffset" : 95
    }, {
      "referenceID" : 148,
      "context" : "SPIONs have been a core component of inorganic nanomedicine [159].",
      "startOffset" : 60,
      "endOffset" : 65
    }, {
      "referenceID" : 144,
      "context" : "However, in 2008 Feridex and in 2012 GastroMARK were withdrawn due to cytotoxicity [155].",
      "startOffset" : 83,
      "endOffset" : 88
    }, {
      "referenceID" : 149,
      "context" : "Dextran-coated SPIONs, Feraheme, approved in 2009 by FDA has been used for the treatment of anemia and chronic kidney disease [160].",
      "startOffset" : 126,
      "endOffset" : 131
    }, {
      "referenceID" : 150,
      "context" : "NanoTherm, 15-nm SPIONs coated with aminosilane, has been recently approved in Europe for selective ablation of glioblastoma and has entered clinical trials in US for localized ablation of prostate cancer [161].",
      "startOffset" : 205,
      "endOffset" : 210
    }, {
      "referenceID" : 151,
      "context" : "It consists of PEGylated gold-silica nanoshell that is optically active in the NIR region of the spectrum [162].",
      "startOffset" : 106,
      "endOffset" : 111
    }, {
      "referenceID" : 152,
      "context" : "Recently, Hafnium oxide nanoparticles, NBTXR3, under phase II/III trials, has also shown utility in treating squamous cell carcinoma by electromagnetic radiation-induced cell death when injected locally [163].",
      "startOffset" : 203,
      "endOffset" : 208
    }, {
      "referenceID" : 153,
      "context" : "Adagen, a PEGylated adenosine deaminase enzyme was the first FDA-approved PEGylated drug in 1990 for severe combined immunodeficiency disease [164].",
      "startOffset" : 142,
      "endOffset" : 147
    }, {
      "referenceID" : 154,
      "context" : "Recently, Plegridy (2014) and Adynovate (2015) have been FDA-approved and are PEGylated biologics for the treatment of multiple sclerosis (MS) and hemophilia, respectively [166,167].",
      "startOffset" : 172,
      "endOffset" : 181
    }, {
      "referenceID" : 155,
      "context" : "Recently, Plegridy (2014) and Adynovate (2015) have been FDA-approved and are PEGylated biologics for the treatment of multiple sclerosis (MS) and hemophilia, respectively [166,167].",
      "startOffset" : 172,
      "endOffset" : 181
    }, {
      "referenceID" : 145,
      "context" : "In 2002, FDA approved Eligard, which consists of Leuprolide acetate and PLGA, for prostate cancer treatment [156].",
      "startOffset" : 108,
      "endOffset" : 113
    }, {
      "referenceID" : 156,
      "context" : "Currently, Opaxio, a biodegradable conjugate of paclitaxel and polyglutamic acid is under clinical phase III trial for drug delivery to head and neck cancer and has been approved for the status of infant drug by FDA [168].",
      "startOffset" : 216,
      "endOffset" : 221
    }, {
      "referenceID" : 157,
      "context" : "Another paclitaxel-based PEG-co-PLA nanomedicine is under phase III trial, Genexol-PM, has shown lower toxicity in the treatment of nonsmall cell lung cancer (NSCLC) and metastatic breast cancer [169].",
      "startOffset" : 195,
      "endOffset" : 200
    }, {
      "referenceID" : 158,
      "context" : "CRLX-101, a cyclodextrin-conjugated camptothecin, is under clinical phase I/II trial for rectal cancer [170].",
      "startOffset" : 103,
      "endOffset" : 108
    }, {
      "referenceID" : 160,
      "context" : "Abraxane has been approved for treatments of NSCLC (2012) and for late stage pancreatic cancer (2014) [173].",
      "startOffset" : 102,
      "endOffset" : 107
    }, {
      "referenceID" : 161,
      "context" : "nanoparticle but bound to rapamycin for treating bladder cancer and cancers with mTOR mutation [174].",
      "startOffset" : 95,
      "endOffset" : 100
    }, {
      "referenceID" : 171,
      "context" : "DNA barcoded nanoparticles for high-throughput in vivo nanoparticle delivery [185].",
      "startOffset" : 77,
      "endOffset" : 82
    }, {
      "referenceID" : 162,
      "context" : "FDA approved AmBisome in 1997, which consists of Amphotericin B encapsulated in the liposome for treatment of fungal infections [175].",
      "startOffset" : 128,
      "endOffset" : 133
    }, {
      "referenceID" : 163,
      "context" : "approval from the FDA for non-tuberculous mycobacterial lung disease [176].",
      "startOffset" : 69,
      "endOffset" : 74
    }, {
      "referenceID" : 164,
      "context" : "These liposomes are expected to show improved efficacy towards HER2-positive breast cancer and further improve the drug efficacy [177].",
      "startOffset" : 129,
      "endOffset" : 134
    }, {
      "referenceID" : 165,
      "context" : "MBP-426 and SGT53, other nanotherapeutic agents under clinical phase I/II trials, are assumed to bind to transferrin receptor (TfR) for active targeting of liposomal encapsulated Oxaliplatin and wild-type p53 DNA, respectively [178].",
      "startOffset" : 227,
      "endOffset" : 232
    }, {
      "referenceID" : 166,
      "context" : "bination of cytarabine and daunorubicin encapsulated in liposome for treatment of acute myeloid leukemia [180].",
      "startOffset" : 105,
      "endOffset" : 110
    }, {
      "referenceID" : 167,
      "context" : "The number is not impressive because the development of methods and standard protocols required for their efficacy, toxicity, and safety testing for clinical use is still in need of standardization [181].",
      "startOffset" : 198,
      "endOffset" : 203
    }, {
      "referenceID" : 168,
      "context" : "The inability to translate nanomedicine platforms from academic reports to industrial scaling processes that comply with GMP and regulatory contexts for human use is still a challenge [182].",
      "startOffset" : 184,
      "endOffset" : 189
    }, {
      "referenceID" : 169,
      "context" : "Several techniques, including particle replication in non-wetting template (PRINT) [183] and coaxial turbulent jet mixer [184] have been introduced in the market, promising efficient bulk nanoparticle synthesis.",
      "startOffset" : 83,
      "endOffset" : 88
    }, {
      "referenceID" : 170,
      "context" : "Several techniques, including particle replication in non-wetting template (PRINT) [183] and coaxial turbulent jet mixer [184] have been introduced in the market, promising efficient bulk nanoparticle synthesis.",
      "startOffset" : 121,
      "endOffset" : 126
    }, {
      "referenceID" : 172,
      "context" : "Also, the development of organon-a-chip platforms, which are biomimetic in vitro models of their human counterparts, in evaluating pharmacokinetics and pharmacodynamics of nanoparticles in pre-clinical trials is an evolving field and will help significantly in toxicity studies of nanoparticle-based therapeutics [186].",
      "startOffset" : 313,
      "endOffset" : 318
    }, {
      "referenceID" : 173,
      "context" : "Also, with the introduction of novel stimuli-responsive nanomaterials [187], we envision similar products in the market that will release the encapsulated drugs on demand.",
      "startOffset" : 70,
      "endOffset" : 75
    }, {
      "referenceID" : 174,
      "context" : "CRISPR/Cas9) [188] safely into cells to be properly established and used efficiently.",
      "startOffset" : 13,
      "endOffset" : 18
    }, {
      "referenceID" : 172,
      "context" : "In addition, organ-on-a-chip systems will likely help expedite interaction, efficacy, and toxicology studies of nanomaterials before going for in vivo investigations or clinical trials [186,189].",
      "startOffset" : 185,
      "endOffset" : 194
    }, {
      "referenceID" : 168,
      "context" : "[182] are expected to expedite FDA approvals that will result in an increased footprint of nanomaterials in the pharmaceutical market.",
      "startOffset" : 0,
      "endOffset" : 5
    } ],
    "year" : 2017,
    "abstractText" : "With the advent of technology, the role of nanomaterials in medicine has grown exponentially in the last few decades. The main advantage of such materials has been exploited in drug delivery applications, due to their effective targeting that in turn reduces systemic toxicity compared to the conventional routes of drug administration. Even though these materials offer broad flexibility based on targeting tissue, disease, and drug payload, the demand for more effective yet highly biocompatible nanomaterialbased drugs is increasing. While therapeutically improved and safe materials have been introduced in nanomedicine platforms, issues related to their degradation rate and bio-distribution still exist, thus making their successful translation to clinical application very challenging. Researchers are constantly improving upon novel nanomaterials that are safer and more effective not only as therapeutic agents but as diagnostic tools as well, making the research in the field of nanomedicine ever more fascinating. In this review, the stress has been made on the evolution of nanomaterials that are under different stages of clinical trials or have been approved by the United States Food and Drug Administration (FDA). © 2017 Elsevier Ltd. All rights reserved.",
    "creator" : "Elsevier"
  }
}